[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 381
1. Ohtsuka K, Ohnishi H, Fujiwara M, Kishino T, Matsushima S, Furuyashiki G, Takei H, Koshiishi Y, Goya T, Watanabe T: Abnormalities of epidermal growth factor receptor in lung squamous-cell carcinomas, adenosquamous carcinomas, and large-cell carcinomas: tyrosine kinase domain mutations are not rare in tumors with an adenocarcinoma component. Cancer; 2007 Feb 15;109(4):741-50
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Abnormalities of epidermal growth factor receptor in lung squamous-cell carcinomas, adenosquamous carcinomas, and large-cell carcinomas: tyrosine kinase domain mutations are not rare in tumors with an adenocarcinoma component.
  • BACKGROUND: Tyrosine kinase domain (TKD) gene mutations of the epidermal growth factor receptor gene (EGFR) have proven to be clinically significant in nonsmall-cell lung cancer (NSCLC), particularly in adenocarcinoma.
  • However, TKD mutations together with deletion mutations in the extracellular domain of EGFR (EGFRvIII) have not been fully investigated in NSCLC except for adenocarcinoma.
  • METHODS: EGFR TKD mutations were investigated using direct sequencing and mutation-specific polymerase chain reaction (PCR), and EGFRvIII mutations were examined using reverse transcriptase-PCR in samples from 42 NSCLC patients and 6 NSCLC cell lines excluding adenocarcinoma.
  • RESULTS: EGFR TKD mutations were detected in 1 of 7 (14%) squamous-cell carcinomas with an adenocarcinoma component and 2 of 4 (50%) adenosquamous carcinomas.
  • In contrast, EGFR TKD mutations were not identified in 24 pure squamous-cell carcinomas without any adenocarcinoma component, 7 large-cell carcinomas, or 6 cell lines.
  • EGFRvIII was detected solely in 1 of 7 large-cell carcinomas (14%), but not in 31 squamous-cell carcinomas, 4 adenosquamous carcinomas, or 6 cell lines.
  • CONCLUSIONS: These results suggest that EGFR TKD mutations are found in NSCLCs with an adenocarcinoma element.
  • [MeSH-major] Carcinoma, Adenosquamous / genetics. Carcinoma, Large Cell / genetics. Carcinoma, Non-Small-Cell Lung / genetics. Carcinoma, Squamous Cell / genetics. Mutation. Receptor, Epidermal Growth Factor / genetics

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17238183.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / epidermal growth factor receptor VIII; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


2. Geyer FC, Lambros MB, Natrajan R, Mehta R, Mackay A, Savage K, Parry S, Ashworth A, Badve S, Reis-Filho JS: Genomic and immunohistochemical analysis of adenosquamous carcinoma of the breast. Mod Pathol; 2010 Jul;23(7):951-60
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genomic and immunohistochemical analysis of adenosquamous carcinoma of the breast.
  • Breast adenosquamous carcinomas are rare tumours characterized by well-developed gland formation intimately admixed with solid nests of squamous cells immersed in a highly cellular spindle cell stroma.
  • Here we studied five cases of adenosquamous carcinomas to determine their genetic profiles and to investigate whether the spindle cell component of these cancers could at least in part stem from the glandular/epithelial components.
  • Five adenosquamous carcinomas of the breast were subjected to (1) immunohistochemical analysis, (2) microdissection and genetic analysis with a high-resolution microarray comparative genomic hybridization platform, and (3) chromogenic in situ hybridization.
  • In conclusion, breast adenosquamous carcinomas are triple-negative cancers that express 'basal' keratins.
  • Some of the spindle cells in adenosquamous carcinomas are derived from the epithelial component, suggesting that adenosquamous carcinomas may also be part of the group of metaplastic breast carcinomas with spindle cell metaplastic elements.
  • [MeSH-major] Breast Neoplasms / genetics. Breast Neoplasms / pathology. Carcinoma, Adenosquamous / genetics. Carcinoma, Adenosquamous / pathology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20453835.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


3. Brody JR, Costantino CL, Potoczek M, Cozzitorto J, McCue P, Yeo CJ, Hruban RH, Witkiewicz AK: Adenosquamous carcinoma of the pancreas harbors KRAS2, DPC4 and TP53 molecular alterations similar to pancreatic ductal adenocarcinoma. Mod Pathol; 2009 May;22(5):651-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenosquamous carcinoma of the pancreas harbors KRAS2, DPC4 and TP53 molecular alterations similar to pancreatic ductal adenocarcinoma.
  • Adenosquamous carcinoma of the pancreas is one of the most aggressive forms of pancreatic cancer.
  • Understanding the common molecular and pathologic features of pancreatic adenosquamous carcinomas could provide critical information for identifying therapeutic targets.
  • Herein, we analyzed the pathologic and molecular features of our series of eight pancreatic adenosquamous carcinomas.
  • The majority of the cases had loss of Dpc4 protein and strong nuclear p53 positivity, similar to the molecular signature found in pancreatic ductal adenocarcinoma.
  • The squamous component was positive for p63 staining and thus p63 labeling was helpful in identifying squamous differentiation in adenosquamous carcinomas with an acantholytic growth pattern.
  • In summary, although pancreatic adenosquamous carcinoma and ductal adenocarcinoma have overlapping pathologic and molecular characteristics, there are distinct differences that may be helpful in diagnostic and therapeutic strategies.
  • [MeSH-major] Carcinoma, Adenosquamous / genetics. Carcinoma, Pancreatic Ductal / genetics. DNA-Binding Proteins / genetics. Pancreatic Neoplasms / genetics. Proto-Oncogene Proteins / genetics. Smad4 Protein / genetics. ras Proteins / genetics

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19270646.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CKAP4 protein, human; 0 / Cadherins; 0 / DNA-Binding Proteins; 0 / KRAS protein, human; 0 / Membrane Proteins; 0 / Proto-Oncogene Proteins; 0 / SMAD4 protein, human; 0 / Smad4 Protein; 0 / TP53TG1 protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 3.6.5.2 / ras Proteins
  •  go-up   go-down


Advertisement
4. Cadieux C, Kedinger V, Yao L, Vadnais C, Drossos M, Paquet M, Nepveu A: Mouse mammary tumor virus p75 and p110 CUX1 transgenic mice develop mammary tumors of various histologic types. Cancer Res; 2009 Sep 15;69(18):7188-97
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The p75 and p110 isoforms of the CUX1 homeodomain protein are overexpressed in breast tumors and cancer cell lines.
  • We report that mammary tumors developed after a long latency period, and although various histopathologies were observed, the proportion of adenosquamous carcinomas was significantly higher in p75 CUX1 than in p110 CUX1 transgenic mice.
  • Interestingly, higher expression of erbB2 mRNA was seen in most tumors, not only solid carcinomas but also adenosquamous carcinomas, whereas higher expression of various Wnt genes and activation of the beta-catenin pathway was observed primarily in adenosquamous carcinomas.
  • [MeSH-minor] Animals. Carcinoma, Adenosquamous / genetics. Carcinoma, Adenosquamous / metabolism. Carcinoma, Adenosquamous / pathology. Caseins / biosynthesis. Caseins / genetics. Female. Humans. Lung Neoplasms / genetics. Lung Neoplasms / secondary. Mammary Tumor Virus, Mouse / genetics. Mice. Mice, Transgenic. Protein Isoforms. RNA, Messenger / biosynthesis. RNA, Messenger / genetics. Receptor, ErbB-2 / biosynthesis. Receptor, ErbB-2 / genetics. Receptor, ErbB-2 / metabolism. Transgenes. Wnt Proteins / metabolism

  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19738070.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CUX1 protein, human; 0 / Caseins; 0 / Homeodomain Proteins; 0 / Nuclear Proteins; 0 / Protein Isoforms; 0 / RNA, Messenger; 0 / Repressor Proteins; 0 / Wnt Proteins; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


5. Ueda Y, Miyatake T, Okazawa M, Kimura T, Miyake T, Fujiwara K, Yoshino K, Nakashima R, Fujita M, Enomoto T: Clonality and HPV infection analysis of concurrent glandular and squamous lesions and adenosquamous carcinomas of the uterine cervix. Am J Clin Pathol; 2008 Sep;130(3):389-400
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clonality and HPV infection analysis of concurrent glandular and squamous lesions and adenosquamous carcinomas of the uterine cervix.
  • We analyzed the clonality and human papillomavirus (HPV) infection status of concurrent glandular and squamous lesions and adenosquamous carcinomas of the uterine cervix to clarify their histogenesis.
  • The glandular and squamous components were clonally different from each other in 7 informative concurrent lesions.
  • HPV was episomal in 2 polyclonal glandular dysplasias (GDs).
  • HPV was in a mixed integrated-episomal form in a monoclonal GD, an adenocarcinoma in situ, and an adenocarcinoma.
  • Both tumor components were monoclonal in origin in 6 adenosquamous carcinomas, with identical patterns of X-chromosomal inactivation and types and physical status of HPV.
  • These results imply that the concurrent glandular and squamous lesions are formed separately, whereas adenosquamous carcinoma is more likely to be a combination tumor of monoclonal origin, and that integration of HPV has an important role in the progression from polyclonal GD through monoclonal expansion to adenocarcinoma in situ and adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / virology. Carcinoma, Adenosquamous / virology. Carcinoma, Squamous Cell / virology. Cervix Uteri / pathology. Cervix Uteri / virology. Endometrial Neoplasms / virology. Papillomavirus Infections / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18701412.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Viral
  •  go-up   go-down


6. Imadome K, Iwakawa M, Nakawatari M, Fujita H, Kato S, Ohno T, Nakamura E, Ohkubo Y, Tamaki T, Kiyohara H, Imai T: Subtypes of cervical adenosquamous carcinomas classified by EpCAM expression related to radiosensitivity. Cancer Biol Ther; 2010 Nov 15;10(10):1019-26
SciCrunch. ArrayExpress: Data: Microarray .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Subtypes of cervical adenosquamous carcinomas classified by EpCAM expression related to radiosensitivity.
  • Adenosquamous carcinoma (ASC) is a relatively uncommon histological subtype of cervical cancer (CC).
  • A point of controversy is the relative prognosis of ASC compared to squamous cell carcinoma (SCC).
  • All adenocarcinoma (AC) patients were classified into one cluster, and most SCC patients fell into the other cluster.
  • In addition, the inhibition of EpCAM expression using siRNA significantly increased radiation-induced cell death in the cervical cell line, ME-180.
  • [MeSH-major] Adenocarcinoma / classification. Antigens, Neoplasm / metabolism. Biomarkers, Tumor / metabolism. Carcinoma, Adenosquamous / classification. Carcinoma, Squamous Cell / classification. Cell Adhesion Molecules / metabolism. Radiation Tolerance / genetics. Uterine Cervical Neoplasms / classification


7. Martinho O, Gonçalves A, Moreira MA, Ribeiro LF, Queiroz GS, Schmitt FC, Reis RM, Longatto-Filho A: KIT activation in uterine cervix adenosquamous carcinomas by KIT/SCF autocrine/paracrine stimulation loops. Gynecol Oncol; 2008 Nov;111(2):350-5
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] KIT activation in uterine cervix adenosquamous carcinomas by KIT/SCF autocrine/paracrine stimulation loops.
  • OBJECTIVES: Uterine adenosquamous carcinoma (ASC) is an uncommon, yet, one of the most aggressive cervical cancer subtype.
  • METHODS: In a series of 30 cases, we studied KIT (CD117), KIT phosphorylated/activated form, as well as KIT ligand, stem cell factor (SCF), by immunohistochemistry.
  • [MeSH-major] Carcinoma, Adenosquamous / enzymology. Proto-Oncogene Proteins c-kit / metabolism. Stem Cell Factor / metabolism. Uterine Cervical Neoplasms / enzymology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18708242.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Stem Cell Factor; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


8. Longatto-Filho A, Pinheiro C, Martinho O, Moreira MA, Ribeiro LF, Queiroz GS, Schmitt FC, Baltazar F, Reis RM: Molecular characterization of EGFR, PDGFRA and VEGFR2 in cervical adenosquamous carcinoma. BMC Cancer; 2009 Jun 29;9:212
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular characterization of EGFR, PDGFRA and VEGFR2 in cervical adenosquamous carcinoma.
  • BACKGROUND: Adenosquamous carcinoma of the uterine cervix is an infrequent but aggressive subtype of cervical cancer.
  • The objective of this study was to investigate EGFR, PDGFRA and VEGFR2 RTKs overexpression and activating gene mutations in a cohort of 30 adenosquamous carcinomas of the uterine cervix.
  • All PDGFRA immunohistochemical reactions were positive and consistently observed in the stromal component, staining fibroblasts and endothelial cells, as well as in the cytoplasm of malignant cells.
  • We also observed the presence of base substitutions in intron 14 (IVS14+3G>A and IVS14+49G>A) in two different cases, and in intron 18 (IVS18-50insA) in 4 cases.
  • CONCLUSION: This is the most extensive analysis of EGFR, PDGFRA and VEGFR2 in cervical adenosquamous carcinomas.
  • Despite the absence of EGFR and PDGFRA activating mutations, the presence of overexpression of these three important therapeutic targets in a subset of cases may be important in predicting the sensitivity of adenosquamous carcinoma to specific anti-RTKs drugs.
  • [MeSH-major] Carcinoma / genetics. Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Receptor, Epidermal Growth Factor / genetics. Receptor, Platelet-Derived Growth Factor alpha / genetics. Uterine Cervical Neoplasms / genetics. Vascular Endothelial Growth Factor Receptor-2 / genetics

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] PLoS Med. 2008 Jan 29;5(1):e19 [18232728.001]
  • [Cites] Curr Opin Investig Drugs. 2008 Dec;9(12):1324-35 [19037839.001]
  • [Cites] Nature. 2001 May 17;411(6835):355-65 [11357143.001]
  • [Cites] Cancer. 2003 May 1;97(9):2196-202 [12712471.001]
  • [Cites] Gynecol Oncol. 2003 Jun;89(3):414-9 [12798704.001]
  • [Cites] Histopathology. 2003 Jul;43(1):33-9 [12823710.001]
  • [Cites] Clin Cancer Res. 2003 Aug 1;9(8):2985-91 [12912946.001]
  • [Cites] Gynecol Oncol. 2003 Nov;91(2):346-53 [14599865.001]
  • [Cites] Gynecol Oncol. 2003 Dec;91(3):558-62 [14675676.001]
  • [Cites] Clin Cancer Res. 2004 Feb 15;10(4):1366-74 [14977838.001]
  • [Cites] J Pathol. 2004 Mar;202(3):313-20 [14991896.001]
  • [Cites] N Engl J Med. 2004 May 20;350(21):2129-39 [15118073.001]
  • [Cites] Biochemistry. 1987 Mar 10;26(5):1443-51 [3494473.001]
  • [Cites] J Clin Pathol. 1993 Feb;46(2):149-53 [8459036.001]
  • [Cites] J Virol. 1993 Aug;67(8):4521-32 [8392596.001]
  • [Cites] Cancer. 1996 Aug 1;78(3):433-40 [8697388.001]
  • [Cites] Clin Cancer Res. 1999 Mar;5(3):577-86 [10100709.001]
  • [Cites] Cell Mol Life Sci. 2004 Dec;61(23):2924-31 [15583854.001]
  • [Cites] Acta Neuropathol. 2005 Feb;109(2):207-10 [15791479.001]
  • [Cites] Oncogene. 2005 Apr 7;24(15):2585-8 [15735736.001]
  • [Cites] Breast Cancer Res. 2005;7(5):R788-95 [16168125.001]
  • [Cites] J Natl Cancer Inst. 2006 Mar 1;98(5):303-15 [16507827.001]
  • [Cites] Mod Pathol. 2006 May;19(5):701-7 [16557278.001]
  • [Cites] Clin Transl Oncol. 2006 Feb;8(2):77-82 [16632420.001]
  • [Cites] Int J Cancer. 2006 Jul 1;119(1):91-8 [16450401.001]
  • [Cites] Semin Oncol. 2006 Aug;33(4):407-20 [16890796.001]
  • [Cites] J Pathol. 2006 Aug;209(4):445-53 [16739104.001]
  • [Cites] Int J Gynecol Pathol. 2007 Jul;26(3):235-41 [17581404.001]
  • [Cites] Drugs. 2007;67(14):2045-75 [17883287.001]
  • [Cites] Oncol Rep. 2007 Nov;18(5):1201-6 [17914573.001]
  • [Cites] Curr Med Chem. 2007;14(23):2495-516 [17979703.001]
  • [Cites] Oncol Rep. 2008 Jan;19(1):65-71 [18097577.001]
  • [Cites] Gynecol Oncol. 2008 Jan;108(1):42-6 [17980406.001]
  • [Cites] Gynecol Oncol. 2008 Jan;108(1):182-90 [18028988.001]
  • [Cites] J Clin Pathol. 2008 Feb;61(2):203-8 [17827398.001]
  • [Cites] PLoS One. 2008;3(2):e1652 [18286204.001]
  • [Cites] Gynakol Geburtshilfliche Rundsch. 2008;48(2):94-100 [18431049.001]
  • [Cites] J Gastroenterol. 2008;43(7):499-508 [18648736.001]
  • [Cites] Int J Gynecol Cancer. 2008 Jul-Aug;18(4):749-54 [17949425.001]
  • [Cites] BMC Cancer. 2008;8:232 [18700025.001]
  • [Cites] Gynecol Oncol. 2008 Sep;110(3 Suppl 2):S72-6 [18544460.001]
  • [Cites] Methods Find Exp Clin Pharmacol. 2008 Sep;30(7):543-88 [18985183.001]
  • [Cites] Gynecol Oncol. 2008 Nov;111(2):350-5 [18708242.001]
  • [Cites] Drugs. 2000;60 Suppl 1:15-23; discussion 41-2 [11129168.001]
  • (PMID = 19563658.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor alpha; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-2
  • [Other-IDs] NLM/ PMC2711112
  •  go-up   go-down


9. Lüttges J, Klöppel G: [Pancreatic ductal adenocarcinoma and its precursors]. Pathologe; 2005 Feb;26(1):12-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pancreatic ductal adenocarcinoma and its precursors].
  • Pancreatic ductal adenocarcinoma is the most frequent malignant pancreatic tumor.
  • Its morphological characteristics are: preferential localization in the head of the pancreas, ductal-glandular tumor structures combined with marked desmoplasia and CEA and MUC1 positivity.
  • Variants of this carcinoma include adenosquamous carcinomas, undifferentiated pleomorphic carcinomas and mixed ductal-endocrine tumors.
  • With the definition of ductal lesions as pancreatic intraepithelial neoplasia, a progression model for pancreatic ductal carcinoma has been developed and corresponding gene alterations have been detected.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma, Pancreatic Ductal / pathology. Precancerous Conditions / pathology

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15630571.001).
  • [ISSN] 0172-8113
  • [Journal-full-title] Der Pathologe
  • [ISO-abbreviation] Pathologe
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Carcinoembryonic Antigen; 0 / Mucin-1
  •  go-up   go-down


10. Vrdoljak E, Boraska Jelavic T, Saratlija-Novakovic Z, Hamm W: Concomitant chemobrachyradiotherapy with ifosfamide and cisplatin followed by consolidation chemotherapy in the treatment of locally advanced adenocarcinoma or adenosquamous carcinoma of the cervix uteri. Eur J Gynaecol Oncol; 2005;26(6):602-4
Hazardous Substances Data Bank. IFOSFAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concomitant chemobrachyradiotherapy with ifosfamide and cisplatin followed by consolidation chemotherapy in the treatment of locally advanced adenocarcinoma or adenosquamous carcinoma of the cervix uteri.
  • The optimal treatment of women with locally advanced adenocarcinoma or adenosquamous carcinoma of the cervix uteri is still undefined.
  • We report a series of four consecutive patients with locally advanced adeno- or adenosquamous carcinomas of the uterine cervix (FIGO Stages IB-IIIB) treated by concomitant chemobrachyradiotherapy with ifosfamide and cisplatin followed by one to four cycles of consolidation chemotherapy with the same drug combination.
  • Now, after a median follow-up of 40 (range: 13.5-61) months all patients still present with no evidence of disease.
  • Despite the low number of patients in this series we may conclude that concomitant chemobrachyradiotherapy with ifosfamide and cisplatin followed by consolidation chemotherapy with the same drug combination is an efficacious treatment of patients with locally advanced adeno- or adenosquamous carcinomas of the cervix uteri.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brachytherapy. Carcinoma, Adenosquamous / drug therapy. Uterine Cervical Neoplasms / drug therapy


11. Morresi-Hauf A, Wöckel W, Kirchner T: [Thymic cyst with initial malignant transformation]. Pathologe; 2008 Jul;29(4):308-10
MedlinePlus Health Information. consumer health - Thymus Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Thymic cyst with initial malignant transformation].
  • We present the case of a 38-year-old woman with a thymus cyst with an incidental tiny adenocarcinoma.
  • Adenocarcinomas and adenosquamous carcinomas of the thymus or in thymus cysts have seldom been reported.
  • These cases were overt invasive carcinomas.
  • Our case is the first report on an incipient adenocarcinoma in a thymus cyst.
  • It demonstrates the importance of thorough histological examination of cystic changes in the thymus, not only for the diagnostic classification of the lesion but also to ensure that a possible malignant change is not overlooked.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma, Adenosquamous / pathology. Cysts / pathology. Thymus Gland / pathology. Thymus Neoplasms / pathology
  • [MeSH-minor] Adult. Cell Transformation, Neoplastic. Diagnosis, Differential. Female. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18389237.001).
  • [ISSN] 1432-1963
  • [Journal-full-title] Der Pathologe
  • [ISO-abbreviation] Pathologe
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


12. McCormack M, Ledermann JA, Hall-Craggs MA, Symonds RP, Warwick V, Simonds H, Fernando I, Hackshaw A: A phase II study of weekly neoadjuvant chemotherapy followed by radical chemoradiation for locally advanced cervical cancer. J Clin Oncol; 2009 May 20;27(15_suppl):5586

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Baseline characteristics were: median age at diagnosis 43 yrs (23-71); 74% squamous-, 20% adeno- and 6% adenosquamous carcinomas; FIGO stage IB2 (11%), II (50%), III (33%), IV (6%).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962391.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Bjerregaard JK, Schønnemann KR, Jensen HA, Vestermark LW, Hansen TP, Pfeiffer P: Biweekly cetuximab and irinotecan as second-line therapy to patients with platinium-resistant gastroesophageal cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e15624

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: All pts had histologically confirmed GE cancer (adeno- or squamous cell carcinoma) and all pts had previously received first line platinum based therapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962695.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Tsubamoto H, Wada R, Kanazawa R, Komori S, Maeda H, Hirota S, Adachi S: Neoadjuvant transarterial chemoembolization (TACE) using cisplatin with the combination of dose-dense intravenous administration of paclitaxel for the locally advanced cervical adenocarcinoma. J Clin Oncol; 2009 May 20;27(15_suppl):e16518

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neoadjuvant transarterial chemoembolization (TACE) using cisplatin with the combination of dose-dense intravenous administration of paclitaxel for the locally advanced cervical adenocarcinoma.
  • : e16518 Background: Adenocarcinoma (including adenosquamous carcinoma) of the uterine cervix has a tendency to early lymph node metastasis and is resistant to radiation therapy, thus results in poor prognosis compared with squamous cell carcinoma.
  • Neoadjuvant chemotherapy (NAC) followed by radical hysterectomy (RH) for bulky cervical adenocarcinoma seems to be an alternative therapy to primary radiation.
  • Eligible criteria were as follows: Histologically diagnosed cervical adeno or adenosquamous carcinoma with FIGO stage IB2-IVA, Age < or equal to 75, PS 0-2, given informed consent.
  • RESULTS: Enrolled patients: 22 (1998-2006), Age: median 51 (33-75), FIGO stage: IB2 (9), IIA-IIB (8), IIIB (3), IVA (2), adeno/adenosquamous: 16/6.
  • 16 of 17 received RH, and no residual malignant cells were found pathologically (pCR) in 3.
  • CONCLUSIONS: TACE with cisplatin and dose dense paclitaxel in the neoadjuvant setting is feasible and effective for cervical adenocarcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960760.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Sugio K, Nagashima A, Nakanishi R, Uchiyama A, Inoue M, Osaki T, Yoshimatsu T, Takenoyama M, Hanagiri T, Yasumoto K: Randomized phase II trial of the biweekly schedule of adjuvant chemotherapy with carboplatin plus paclitaxel versus carboplatin plus gemcitabine in patients with non-small cell lung cancer (NSCLC). J Clin Oncol; 2009 May 20;27(15_suppl):7562

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Randomized phase II trial of the biweekly schedule of adjuvant chemotherapy with carboplatin plus paclitaxel versus carboplatin plus gemcitabine in patients with non-small cell lung cancer (NSCLC).
  • The primary endpoint was compliance, and secondary endpoints were the disease free survival (DFS) and toxicity.
  • The patients were stratified by gender, histology (adenoca vs. non-adenoca) and disease stage.
  • The histologic types included adenocarcinoma (n=51), squamous cell carcinoma (n=18), large cell carcinoma (n=5), and adenosquamous cell carcinoma (n=1).
  • Twenty-one of 39 pts (54%) in arm A and 25 of 36 pts (69%) in arm B completed 8 cycles, and 59% in arm A and 81% in arm B completed ≥6 cycles.
  • Up to 12/2008, 11 of 39 pts in arm A and 13 of 36 pts in arm B had recurrent disease, but no significant difference was observed.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963358.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Ishii H, Furuse J, Boku N, Okusaka T, Ikeda M, Ohkawa S, Fukutomi A, Hamamoto Y, Nakamura K, Fukuda H: Phase II study of gemcitabine chemotherapy alone for locally advanced pancreatic carcinoma: JCOG 0506. J Clin Oncol; 2009 May 20;27(15_suppl):e15578

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of gemcitabine chemotherapy alone for locally advanced pancreatic carcinoma: JCOG 0506.
  • METHODS: Eligibility criteria included the following: patients (pts) with histologically or cytologically proven pancreatic adenocarcinoma or adenosquamous carcinoma, pts with UICC clinical stage III (T4N0-1 and M0), all lesions are assumed to be included in the radiation field of 15 cm square, age 20 or older, no prior treatment for LAPC, ECOG performance status of 0, 1 or 2, and adequate organ function.
  • Gem was given intravenously at a dose of 1,000 mg/m2 over 30 minutes on days 1, 8 and 15, repeated every 4 weeks until disease progression.
  • Serum CA 19-9 level was reduced by >50% in 37.5% of 40 pts with baseline CA19-9 >100U/ml.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962370.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Amălinei C, Balan R, Stolnicu S, Rădulescu D, Boeru C, Cotuţiu C: Adenosquamous cervical carcinoma morphological characteristics. Rev Med Chir Soc Med Nat Iasi; 2005 Apr-Jun;109(2):343-6
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenosquamous cervical carcinoma morphological characteristics.
  • Adenosquamous carcinomas range between 5-25% of cervical cancers and are composed by an admixture of malignant squamous and glandular elements.
  • Differential diagnosis with endometrioid adenocarcinoma of the cervix with squamous metaplasia was made.
  • Four cases (26.66%) were subtyped as clear cell adenosquamous carcinomas and 2 cases (13.33%) were subtyped as glassy cell carcinomas, exhibiting finely granular ground glass type cytoplasm.
  • 93.33% of cases exhibited a poorly differentiated squamous component and 66.66% of cases exhibited a well differentiated glandular component.
  • Squamous intraepithelial lesions in overlying epithelium was observed in 4 cases (26.66%).
  • One case, diagnosed as glassy cell subtype, presented regional lymph node metastases.
  • Our study concluded the occurrence of adenosquamous cervical carcinomas at a similar age with squamous cervical carcinomas in the investigated group of patients.
  • As adenosquamous cervical carcinomas are considered expressions of a biphasic differentiation of a single pluripotential sub-columnar reserve cell, a similar degree of differentiation of the two components would be expected.
  • Although, we registered a degree of variability in grading of the two components, with a tendency of squamous component toward poorly differentiated aspect and a slightly dominant aspect of well differentiated glandular pattern.
  • [MeSH-major] Carcinoma, Adenosquamous / pathology. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Diagnosis, Differential. Female. Humans. Middle Aged. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16607797.001).
  • [ISSN] 0048-7848
  • [Journal-full-title] Revista medico-chirurgicală̆ a Societă̆ţ̜ii de Medici ş̧i Naturaliş̧ti din Iaş̧i
  • [ISO-abbreviation] Rev Med Chir Soc Med Nat Iasi
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Romania
  •  go-up   go-down


18. Kwon KY, Ro JY, Singhal N, Killen DE, Sienko A, Allen TC, Zander DS, Barrios R, Haque A, Cagle PT: MUC4 expression in non-small cell lung carcinomas: relationship to tumor histology and patient survival. Arch Pathol Lab Med; 2007 Apr;131(4):593-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MUC4 expression in non-small cell lung carcinomas: relationship to tumor histology and patient survival.
  • It is found in normal adult airway epithelium, non-small cell lung carcinoma (NSCLC) and in other human malignancies independent of mucus secretion.
  • RESULTS: MUC4 was frequently expressed in adenocarcinomas (151/187 [81%]), squamous cell carcinomas (69/ 88 [78%]), adenosquamous carcinomas (6/8 [75%]), and large cell carcinomas (33/60 [55%]).
  • High levels of expression (combined score, 2+/3+) for MUC4 were more characteristic of adenocarcinomas (126/187 [68%]) and adenosquamous carcinomas (6/8 [75%]) than of squamous cell carcinomas (46/88 [52%]) and large cell carcinomas (17/60 [28%]) (P < .001).
  • In patients with stage I and II adenocarcinoma, there was a trend toward longer patient survival with higher levels of MUC4 immunoreactivity compared with lower levels (P = .11).
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / mortality. Carcinoma, Non-Small-Cell Lung / pathology. Lung Neoplasms / mortality. Lung Neoplasms / pathology. Mucins / biosynthesis

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17425390.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / MUC4 protein, human; 0 / Mucin-4; 0 / Mucins
  •  go-up   go-down


19. Jancar N, Kocjan BJ, Poljak M, Lunar MM, Bokal EV: Distribution of human papillomavirus genotypes in women with cervical cancer in Slovenia. Eur J Obstet Gynecol Reprod Biol; 2009 Aug;145(2):184-8
MedlinePlus Health Information. consumer health - Cervical Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • HPV positive samples were more frequent among squamous cell carcinomas than among adenocarcinomas/adenosquamous carcinomas (95.8% versus 85.5%; P=0.003).
  • HPV 16 was more frequently found in squamous cell carcinomas than in adenocarcinomas/adenosquamous carcinomas (69.9% versus 37.5%; P<0.001), while the opposite was true for HPV 18 (6% versus 41.7%; P<0.001).

  • Genetic Alliance. consumer health - Cervical cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19477061.001).
  • [ISSN] 1872-7654
  • [Journal-full-title] European journal of obstetrics, gynecology, and reproductive biology
  • [ISO-abbreviation] Eur. J. Obstet. Gynecol. Reprod. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / DNA, Viral; 0 / Papillomavirus Vaccines
  •  go-up   go-down


20. Lennerz JK, Perry A, Mills JC, Huettner PC, Pfeifer JD: Mucoepidermoid carcinoma of the cervix: another tumor with the t(11;19)-associated CRTC1-MAML2 gene fusion. Am J Surg Pathol; 2009 Jun;33(6):835-43
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucoepidermoid carcinoma of the cervix: another tumor with the t(11;19)-associated CRTC1-MAML2 gene fusion.
  • Mucoepidermoid carcinoma (MEC) of the uterine cervix is a controversial entity.
  • By strict morphologic criteria, the tumor has features identical to those of salivary gland MEC and is characterized by nests composed of 3 cell types (epidermoid, intermediate, and mucin producing) in the absence of overt glandular differentiation.
  • Given the morphologic similarity between MEC of the cervix and MEC of the salivary glands, we sought to determine if MEC of the cervix harbors the t(11;19)(q21;p13) characteristic of MEC of the major and minor salivary glands, a rearrangement that results in fusion of the cyclic adenosine 3',5' monophosphate coactivator CRTC1 to the Notch coactivator MAML2.
  • We identified 7 cervical tumors from our departmental files and performed reverse transcription-polymerase chain reaction and fluorescence in situ hybridization-based molecular analysis for rearrangements of CRTC1 and MAML2; 14 conventional cervical adenosquamous carcinomas were used as controls.
  • All MEC showed aberrations of at least 1 of the loci, whereas none of the cervical adenosquamous carcinomas harbored rearrangements or amplification of either locus.
  • Our results demonstrate that cervical tumors defined as MEC by strict morphologic criteria harbor genetic aberrations involving the genes characteristically rearranged in MEC of the salivary glands, and suggest that cervical MEC is an entity distinct from conventional cervical adenosquamous carcinoma.
  • The development of drug therapy targeted to the genes rearranged in MEC underscores the importance of correct classification of cervical MEC because the diagnosis may hold therapeutic implications different from other cervical malignancies.

  • Genetic Alliance. consumer health - Mucoepidermoid carcinoma.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19092631.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / DK079798-01A2; United States / NIDDK NIH HHS / DK / K08 DK066062; United States / NIDDK NIH HHS / DK / R01 DK079798; United States / NIDDK NIH HHS / DK / R01 DK079798-01A2; United States / NIDDK NIH HHS / DK / K08 DK066062-05; United States / NIDDK NIH HHS / DK / DK066062-05
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CRTC1 protein, human; 0 / DNA-Binding Proteins; 0 / MAML2 protein, human; 0 / Nuclear Proteins; 0 / Oncogene Proteins, Fusion; 0 / Transcription Factors
  •  go-up   go-down


21. He YT, Wang XJ, Gong J, Chen N, Zhou Q: Primary adenosquamous carcinoma of the jejunum. Pathol Int; 2005 Sep;55(9):590-5
MedlinePlus Health Information. consumer health - Intestinal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary adenosquamous carcinoma of the jejunum.
  • Adenosquamous carcinomas of the small intestine are extremely rare, with only three documented jejunal and three ileal cases being reported in the English-language medical literature.
  • Presented herein is a case of primary jejunal adenosquamous carcinoma in an 80-year-old woman.
  • The jejunal carcinoma consisted predominantly of a squamous component throughout the tumor but peritoneal nodules carrying metastases from the adenocarcinoma element were noted, making it the first case of jejunal adenosquamous carcinoma with metastases from the adenocarcinoma component.
  • The finding that metastases could arise from the minor component of a jejunal adenosquamous carcinoma indicates that an accurate diagnosis must be based upon thorough examination of both the primary and the metastases, not just mesenteric nodule biopsy alone.
  • Histological foci of closely intermingled squamous and glandular components with apparent morphological transition were noted, indicating the pathogenetic possibility that the squamous component might arise by transformation from the glandular element.
  • The squamous component was strongly positive with immunostaining for p63 (nuclear staining) and for cytokeratin 10/13 (cytoplasmic staining), while the adenocarcinoma element was negative.
  • The immunohistochemical results suggest that p63 and cytokeratin 10/13 might be useful in identifying squamous differentiation in jejunal carcinoma.
  • [MeSH-major] Carcinoma, Adenosquamous / secondary. Jejunal Neoplasms / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Cell Nucleus / chemistry. Cell Nucleus / pathology. Cytoplasm / chemistry. Cytoplasm / pathology. DNA-Binding Proteins. Fatal Outcome. Female. Genes, Tumor Suppressor. Humans. Immunoenzyme Techniques. Keratins / analysis. Phosphoproteins / analysis. Trans-Activators / analysis. Transcription Factors. Tumor Suppressor Proteins

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16143036.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / Phosphoproteins; 0 / TP63 protein, human; 0 / Trans-Activators; 0 / Transcription Factors; 0 / Tumor Suppressor Proteins; 68238-35-7 / Keratins
  •  go-up   go-down


22. Howell-Jones R, Bailey A, Beddows S, Sargent A, de Silva N, Wilson G, Anton J, Nichols T, Soldan K, Kitchener H, Study Group Collaborators: Multi-site study of HPV type-specific prevalence in women with cervical cancer, intraepithelial neoplasia and normal cytology, in England. Br J Cancer; 2010 Jul 13;103(2):209-16
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: The prevalence of HPV 16 and/or 18 (with or without another high-risk (HR) type) was 76% in squamous cell carcinomas, 82% in adeno/adenosquamous carcinomas and 63% and 91% in CIN3 and CGIN, respectively.
  • CONCLUSION: Pre-immunisation, high-grade cervical disease in England was predominantly associated with HPV 16 and/or 18, which promises a high impact from HPV immunisation in due course.
  • Second-generation vaccines and screening strategies need to consider the best ways to detect and prevent disease due to the remaining HR HPV types.
  • [MeSH-minor] Adenocarcinoma / virology. Adult. Biopsy. England / epidemiology. Female. Human papillomavirus 16 / isolation & purification. Human papillomavirus 18 / isolation & purification. Humans. Middle Aged. Neoplasms, Squamous Cell / virology. Papillomavirus Vaccines. Prevalence

  • Genetic Alliance. consumer health - Cervical Intraepithelial Neoplasia.
  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Vaccine. 2010 May 28;28(24):4091-102 [19909831.001]
  • [Cites] Br J Cancer. 2010 Mar 2;102(5):930-2 [20145611.001]
  • [Cites] Int J Cancer. 2009 Nov 15;125(10):2425-7 [19585507.001]
  • [Cites] Lancet. 2009 Jul 25;374(9686):301-14 [19586656.001]
  • [Cites] Lancet Oncol. 2009 Apr;10(4):321-2 [19350698.001]
  • [Cites] J Infect Dis. 2009 Apr 1;199(7):926-35 [19236279.001]
  • [Cites] Br J Cancer. 2008 Dec 2;99(11):1929-33 [19034285.001]
  • [Cites] BMJ. 2008;337:a769 [18640957.001]
  • [Cites] Int J Gynecol Cancer. 2006 May-Jun;16(3):1025-31 [16803480.001]
  • [Cites] Br J Cancer. 2006 Jul 3;95(1):56-61 [16773068.001]
  • [Cites] Int J Cancer. 1999 Sep 24;83(1):66-9 [10449610.001]
  • [Cites] Hum Pathol. 1993 Apr;24(4):432-7 [8387954.001]
  • [Cites] Lancet. 1992 May 2;339(8801):1070-3 [1349102.001]
  • [Cites] Br J Cancer. 2004 Aug 31;91(5):942-53 [15292939.001]
  • [Cites] Int J Cancer. 2004 Aug 20;111(2):278-85 [15197783.001]
  • [Cites] J Clin Pathol. 2004 Jan;57(1):68-72 [14693839.001]
  • [Cites] Br J Cancer. 2003 Jul 7;89(1):88-93 [12838306.001]
  • [Cites] Br J Cancer. 2003 Jan 13;88(1):63-73 [12556961.001]
  • [Cites] Int J Cancer. 2011 Feb 15;128(4):927-35 [20473886.001]
  • [Cites] Br J Cancer. 2000 Apr;82(7):1348-52 [10755413.001]
  • [CommentIn] Br J Cancer. 2010 Jul 13;103(2):157-8 [20628394.001]
  • [ErratumIn] Br J Cancer. 2010 Sep 7;103(6):928
  • (PMID = 20628396.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Papillomavirus Vaccines
  • [Other-IDs] NLM/ PMC2906740
  • [Investigator] Bailey A; Kitchener H; Sargent A; Beddows S; Lowndes C; Parry J; Soldan K; Bullock P; Cross P; Jones M; Johnson T; Lonsdale R; Wood R; Taylor C; Patnick J; Singh N; Smith J; Waddell C; Ganesan R; Bentley L; Adams J; Young M; McGloin J
  •  go-up   go-down


23. Jiang L, Ji N, Zhou Y, Li J, Liu X, Wang Z, Chen Q, Zeng X: CAL 27 is an oral adenosquamous carcinoma cell line. Oral Oncol; 2009 Nov;45(11):e204-7
MedlinePlus Health Information. consumer health - Oral Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CAL 27 is an oral adenosquamous carcinoma cell line.
  • CAL 27 is one of the most frequently used cell lines in the field of oral squamous cell carcinoma (OSCC) studying.
  • Then, we performed tumor formation assay, HE staining and immunohistochemistry assay to further study the growing characteristics and histopathological diagnosis of CAL 27 xenografts.
  • The CAL 27 xenografts were then diagnosed as oral adenosquamous carcinomas.
  • Thus CAL 27 appears to be an oral adenosquamous carcinoma cell line.
  • [MeSH-major] Carcinoma, Adenosquamous / pathology. Cell Line, Tumor / pathology. Mouth Neoplasms / pathology
  • [MeSH-minor] Carcinoma / pathology. Carcinoma, Squamous Cell. Head and Neck Neoplasms / pathology. Humans. Neoplasms, Squamous Cell / pathology. Transplantation, Heterologous

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19631575.001).
  • [ISSN] 1879-0593
  • [Journal-full-title] Oral oncology
  • [ISO-abbreviation] Oral Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] Carcinoma, squamous cell of head and neck
  •  go-up   go-down


24. Perera SA, Li D, Shimamura T, Raso MG, Ji H, Chen L, Borgman CL, Zaghlul S, Brandstetter KA, Kubo S, Takahashi M, Chirieac LR, Padera RF, Bronson RT, Shapiro GI, Greulich H, Meyerson M, Guertler U, Chesa PG, Solca F, Wistuba II, Wong KK: HER2YVMA drives rapid development of adenosquamous lung tumors in mice that are sensitive to BIBW2992 and rapamycin combination therapy. Proc Natl Acad Sci U S A; 2009 Jan 13;106(2):474-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HER2YVMA drives rapid development of adenosquamous lung tumors in mice that are sensitive to BIBW2992 and rapamycin combination therapy.
  • Here we demonstrate that inducible expression of the most common HER2 mutant (HER2(YVMA)) in mouse lung epithelium causes invasive adenosquamous carcinomas restricted to proximal and distal bronchioles.
  • Continuous expression of HER2(YVMA) is essential for tumor maintenance, suggesting a key role for HER2 in lung adenosquamous tumorigenesis.
  • Based on these findings, clinical testing of the BIBW2992/rapamycin combination in non-small cell lung cancer patients with tumors expressing HER2 mutations is warranted.

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. SIROLIMUS .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 2004 Sep 30;431(7008):525-6 [15457249.001]
  • [Cites] Semin Oncol. 2004 Feb;31(1 Suppl 1):75-82 [14981584.001]
  • [Cites] Cell. 1989 Jul 28;58(2):287-92 [2568888.001]
  • [Cites] Oncogene. 1991 Jul;6(7):1189-94 [1713661.001]
  • [Cites] AJR Am J Roentgenol. 1994 Aug;163(2):301-6 [8037019.001]
  • [Cites] EMBO J. 1997 Apr 1;16(7):1647-55 [9130710.001]
  • [Cites] Cancer Res. 2005 Mar 1;65(5):1642-6 [15753357.001]
  • [Cites] Cancer. 2005 May 1;103(9):1865-73 [15770690.001]
  • [Cites] Cancer Cell. 2006 Jun;9(6):485-95 [16730237.001]
  • [Cites] Cancer Cell. 2006 Jul;10(1):25-38 [16843263.001]
  • [Cites] Clin Cancer Res. 2006 Jul 15;12(14 Pt 2):4372s-4376s [16857813.001]
  • [Cites] Clin Cancer Res. 2006 Dec 15;12(24):7242-51 [17189395.001]
  • [Cites] Cancer Cell. 2007 Jul;12(1):81-93 [17613438.001]
  • [Cites] Oncogene. 2007 Jul 26;26(34):5023-7 [17311002.001]
  • [Cites] Oncogene. 2008 Aug 7;27(34):4702-11 [18408761.001]
  • [Cites] Nat Rev Mol Cell Biol. 2001 Feb;2(2):127-37 [11252954.001]
  • [Cites] EMBO J. 2001 Apr 2;20(7):1726-38 [11285236.001]
  • [Cites] Genes Dev. 2001 Dec 15;15(24):3249-62 [11751631.001]
  • [Cites] Semin Oncol. 2002 Feb;29(1 Suppl 4):59-65 [11894015.001]
  • [Cites] Mol Cell. 2003 Feb;11(2):495-505 [12620236.001]
  • [Cites] Ann Oncol. 2004 Jan;15(1):19-27 [14679114.001]
  • [Cites] Trends Mol Med. 2004 Oct;10(10):481-6 [15464447.001]
  • (PMID = 19122144.001).
  • [ISSN] 1091-6490
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P20 CA090578; United States / NCI NIH HHS / CA / R01 CA122794; United States / NCI NIH HHS / CA / P20 CA90578; United States / NCI NIH HHS / CA / R01 CA90687; United States / NIA NIH HHS / AG / R01 AG2400401; United States / NCI NIH HHS / CA / R01 CA090687
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BIBW 2992; 0 / Quinazolines; EC 2.7.10.1 / Erbb2 protein, mouse; EC 2.7.10.1 / Receptor, ErbB-2; W36ZG6FT64 / Sirolimus
  • [Other-IDs] NLM/ PMC2626727
  •  go-up   go-down


25. Ishibashi H, Akamatsu H, Kojima K, Usui H, Akashi T, Sunamori M: Good syndrome with thymic adenosquamous carcinoma--report of a case. Ann Thorac Cardiovasc Surg; 2007 Feb;13(1):50-2
MedlinePlus Health Information. consumer health - Thymus Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Good syndrome with thymic adenosquamous carcinoma--report of a case.
  • A 68-year-old man with recurrent bilateral severe pneumonia and invasive thymic carcinoma was admitted to our hospital.
  • The tumor was mainly composed of type C, adenosquamous carcinoma, and found to have a small area of types B2 and B3 thymoma.
  • History and laboratory findings were compatible with the diagnosis of Good syndrome.
  • Although there are some reports of thymic carcinoma arising from thymoma, this is the first report of co-existence of adenosquamous carcinomas and thymoma with Good syndrome as far as reviewed articles.
  • Thymic carcinoma with severe infection should be examined carefully for co-existence of thymoma, and co-existence of thymoma and thymic carcinoma suggests a close histogenetic relationship between the 2 tumors.
  • [MeSH-major] Carcinoma, Adenosquamous. Paraneoplastic Syndromes. Thymoma. Thymus Neoplasms

  • Genetic Alliance. consumer health - Good Syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17392673.001).
  • [ISSN] 1341-1098
  • [Journal-full-title] Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia
  • [ISO-abbreviation] Ann Thorac Cardiovasc Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


26. Pera M, Pera M, de Bolós C, Brito MJ, Palacín A, Grande L, Cardesa A, Poulsom R: Duodenal-content reflux into the esophagus leads to expression of Cdx2 and Muc2 in areas of squamous epithelium in rats. J Gastrointest Surg; 2007 Jul;11(7):869-74
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Duodenal-content reflux into the esophagus leads to expression of Cdx2 and Muc2 in areas of squamous epithelium in rats.
  • The molecular events responsible for the transdifferentiation of epithelial cells of the esophagus to a columnar cell type are not well understood.
  • Cdx2 has been detected in Barrett's esophagus, so we sought evidence of Cdx2 expression during the process of transdifferentiation of the esophageal squamous epithelium into a glandular phenotype.
  • Five animals developed glandular metaplasia and adenosquamous carcinoma, two developed only glandular metaplasia, and two had adenosquamous carcinoma alone.
  • Nuclear Cdx2 expression was detected in 57% (four of seven) and 43% (three of seven) of foci of glandular metaplasia and adenosquamous carcinomas, respectively.
  • Cdx2 staining was detectable in some squamous and some mucus secreting cells.
  • Perinuclear and perivacuolar staining of Muc2 was detected focally in 71% (five of seven) and 57% (four of seven) of areas with glandular metaplasia and adenosquamous carcinoma, respectively.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17440788.001).
  • [ISSN] 1091-255X
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Homeodomain Proteins; 0 / Muc2 protein, rat; 0 / Mucin-2; 0 / Mucins; 0 / Trans-Activators; 156560-97-3 / Cdx-2-3 protein
  •  go-up   go-down


27. Hong SM, Cho H, Moskaluk CA, Frierson HF Jr, Yu E, Ro JY: CDX2 and MUC2 protein expression in extrahepatic bile duct carcinoma. Am J Clin Pathol; 2005 Sep;124(3):361-70
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CDX2 and MUC2 protein expression in extrahepatic bile duct carcinoma.
  • Although CDX2-mediated intestinal metaplasia and its association with gastric and esophageal carcinoma have been well described, its function in extrahepatic bile duct (EBD) carcinoma remains unclear.
  • CDX2 and MUC2 expression were examined in 193 EBD carcinomas, and observed in 37.3% and 42.0%, respectively.
  • Both CDX2 and MUC2 were observed in 27.4%. CDX2 (P<.001) and MUC2 (P<.001) were correlated with histologic subtypes and present, respectively, in all intestinal-type adenocarcinomas and mucinous carcinomas, 12 (71%) and 13 (76%) of 17 papillary carcinomas, 2 (40%) and 2 (40%) of 5 adenosquamous carcinomas, and 28.4% and 33.5% of adenocarcinomas, not otherwise specified.
  • Expression of CDX2 and MUC2 supports that intestinal differentiation is present in specific subtypes of EBD carcinomas, and their expression status correlates with patients' overall survival.

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16191504.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CDX2 protein, human; 0 / Homeodomain Proteins; 0 / MUC2 protein, human; 0 / Mucin-2; 0 / Mucins
  •  go-up   go-down


28. Bastide K, Ugolin N, Levalois C, Bernaudin JF, Chevillard S: Are adenosquamous lung carcinomas a simple mix of adenocarcinomas and squamous cell carcinomas, or more complex at the molecular level? Lung Cancer; 2010 Apr;68(1):1-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Are adenosquamous lung carcinomas a simple mix of adenocarcinomas and squamous cell carcinomas, or more complex at the molecular level?
  • Adenocarcinomas (AC), squamous cell carcinomas (SCC) and adenosquamous carcinomas (ASC) are three histological subtypes of non-small-cell lung carcinomas (NSCLC).
  • ASC are morphologically mixed tumours that contain the two cell components AC and SCC.
  • In conclusion, the ASC mixed lung tumours are more complex than simple mixes of AC and SCC components.
  • [MeSH-major] Adenocarcinoma / genetics. Carcinoma, Adenosquamous / genetics. Carcinoma, Squamous Cell / genetics. Lung / metabolism. Lung Neoplasms / genetics
  • [MeSH-minor] Animals. Cell Line, Tumor. Cell Transformation, Neoplastic. DNA Mutational Analysis. GATA6 Transcription Factor / genetics. GATA6 Transcription Factor / metabolism. Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Genes, ras / genetics. MAP Kinase Signaling System / genetics. Microarray Analysis. Mucin-1 / genetics. Mucin-1 / metabolism. Radon / toxicity. Rats. Rats, Sprague-Dawley. Receptor, Notch2 / genetics. Receptor, Notch2 / metabolism

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. RADON, RADIOACTIVE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 20004040.001).
  • [ISSN] 1872-8332
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / GATA6 Transcription Factor; 0 / Gata6 protein, rat; 0 / Mucin-1; 0 / Receptor, Notch2; Q74S4N8N1G / Radon
  • [Number-of-references] 61
  •  go-up   go-down


29. Volgger B, Aspisirengil C, Genser-Krimbacher E, Ciresa-Koenig A, Daxenbichler G, Fuchs D, Windbichler G, Marth C: Prognostic significance of TPA versus SCC-Ag, CEA and neopterin in carcinoma of the uterine cervix. Cancer Lett; 2008 Apr 18;262(2):183-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of TPA versus SCC-Ag, CEA and neopterin in carcinoma of the uterine cervix.
  • INTRODUCTION: Prognostic significance of squamous cell carcinoma antigen (SCC-Ag), tissue polypeptide antigen (TPA), carcinoembryonic antigen (CEA) and neopterin in cervical cancer patients was compared.
  • RESULTS: Median age was 52 years, 85% squamous cell carcinomas, 15% adeno- or adenosquamous carcinomas were seen.
  • In 36% Fédération Internationale de Gynécologie et d'Obstétrique (FIGO) stage I, 24% stage II, 32% stage III and 8% stage IV was diagnosed.
  • [MeSH-major] Antigens, Neoplasm / analysis. Biomarkers, Tumor / analysis. Carcinoembryonic Antigen / analysis. Neopterin / analysis. Serpins / analysis. Tissue Polypeptide Antigen / analysis. Uterine Cervical Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carcinoma, Adenosquamous / diagnosis. Carcinoma, Squamous Cell / diagnosis. Female. Humans. Middle Aged. Prognosis. Survival Analysis

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18226853.001).
  • [ISSN] 0304-3835
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Carcinoembryonic Antigen; 0 / Serpins; 0 / Tissue Polypeptide Antigen; 0 / squamous cell carcinoma-related antigen; 670-65-5 / Neopterin
  •  go-up   go-down


30. Lada PE, Taborda B, Sánchez M, Tommasino J, Rosso FF, Gramática L, Alecha Gil J, Echenique Elizondo M: [Adenosquamous and squamous carcinoma of the gallbladder]. Cir Esp; 2007 Apr;81(4):202-6
MedlinePlus Health Information. consumer health - Gallbladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Adenosquamous and squamous carcinoma of the gallbladder].
  • [Transliterated title] Carcinoma adenoescamoso y epidermoide de la vesícula biliar.
  • INTRODUCTION: Squamous and adenosquamous carcinomas of the gallbladder have poor prognosis.
  • MATERIAL AND METHOD: We performed a retrospective observational study of five patients with squamous or adenosquamous carcinoma of the gallbladder.
  • None of the patients had jaundice and all had gallstone disease.
  • Pathologic analysis revealed epidermoid carcinoma in two patients and adenosquamous carcinoma in three patients.
  • CONCLUSIONS: In both histological types of gallbladder carcinoma, treatment depends on the grade of local and regional invasion and tumor spread at diagnosis.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma, Squamous Cell / pathology. Gallbladder Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17403356.001).
  • [ISSN] 0009-739X
  • [Journal-full-title] Cirugía española
  • [ISO-abbreviation] Cir Esp
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


31. Hong SM, Kim MJ, Jang KT, Yoon GS, Cho H, Frierson HF, Yu E: Adenosquamous carcinoma of extrahepatic bile duct: clinicopathologic study of 12 cases. Int J Clin Exp Pathol; 2008;1(2):147-56
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenosquamous carcinoma of extrahepatic bile duct: clinicopathologic study of 12 cases.
  • Adenosquamous carcinoma is a rare histologic subtype of extrahepatic bile duct (EBD) carcinoma and limited information is available on its clinicopathologic characteristics.
  • Twelve cases of adenosquamous carcinoma were collected from 3 institutions and their clinicopathologic characteristics were examined and compared with those of 176 EBD adenocarcinomas.
  • The adenocarcinoma component was more often seen at the surface of the tumor (7 of 12 cases, 58%), while the squamous carcinoma component was slightly more frequent at the advanced edge (7 of 12 cases, 58%).
  • Immunohistochemistry, available in 10 cases, revealed that S100A2 was positive in the squamous carcinoma component in all 10 cases (100%), while it was present in the adenocarcinoma component in only 2 of 10 cases (20%, chi-square test, p=0.001).
  • Patients with adenosquamous carcinomas had worse survival (median survival, 11 months) than those with adenocarcinoma (median survival, 32 months; log-rank test, p=0.003).
  • Patients with predominant squamous cell carcinoma component at the leading edge had worse survival than those without it.
  • In conclusion, patients with adenosquamous carcinoma demonstrated worse survival than those with pure adenocarcinoma.
  • S100A2 immunohistochemical staining may be helpful in detecting the squamous component.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2007 Feb;31(2):199-206 [17255764.001]
  • [Cites] J Gastroenterol. 2000;35(6):465-71 [10864356.001]
  • [Cites] Cancer. 2005 Aug 15;104(4):802-10 [15959914.001]
  • [Cites] J Gastroenterol. 2005 Feb;40(2):192-9 [15770404.001]
  • [Cites] Dis Colon Rectum. 1999 Feb;42(2):258-63 [10211505.001]
  • [Cites] Clin Cancer Res. 1997 Dec;3(12 Pt 1):2309-16 [9815629.001]
  • [Cites] Diagn Cytopathol. 1996 Nov;15(4):322-4 [8982588.001]
  • [Cites] Ryoikibetsu Shokogun Shirizu. 1996;(9):61-3 [8705560.001]
  • [Cites] Nihon Kyobu Shikkan Gakkai Zasshi. 1994 Feb;32(2):161-7 [8164404.001]
  • [Cites] J Gastroenterol Hepatol. 1993 Nov-Dec;8(6):607-12 [8280849.001]
  • [Cites] J Surg Oncol. 1986 Oct;33(2):140-2 [3531727.001]
  • [Cites] Ann Thorac Surg. 1987 Nov;44(5):462-6 [3675050.001]
  • [Cites] J Surg Oncol. 1980;15(1):29-35 [7421268.001]
  • [Cites] South Med J. 1978 Feb;71(2):216-9 [622635.001]
  • [Cites] Methods Mol Biol. 2005;289:209-22 [15502186.001]
  • [Cites] Br J Cancer. 2004 Oct 18;91(8):1515-24 [15467767.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Oct 1;322(4):1111-22 [15336958.001]
  • [Cites] Biochem Cell Biol. 2004 Aug;82(4):508-15 [15284904.001]
  • [Cites] Gastrointest Endosc. 2004 Aug;60(2):300-4 [15278069.001]
  • [Cites] Tumour Biol. 2004 Jan-Apr;25(1-2):31-40 [15192310.001]
  • [Cites] Chir Ital. 2004 Mar-Apr;56(2):289-95 [15152526.001]
  • [Cites] Gynecol Oncol. 2003 Dec;91(3):558-62 [14675676.001]
  • [Cites] Cancer. 2003 May 1;97(9):2196-202 [12712471.001]
  • [Cites] Cancer Res. 2002 Dec 1;62(23):6823-6 [12460893.001]
  • [Cites] Histol Histopathol. 2002 Jan;17(1):123-30 [11813862.001]
  • [Cites] Pathologica. 2000 Oct;92(5):323-6 [11198466.001]
  • [Cites] Int J Mol Med. 2000 Nov;6(5):539-42 [11029520.001]
  • [Cites] Neoplasia. 2006 Oct;8(10):843-50 [17032501.001]
  • (PMID = 18784802.001).
  • [ISSN] 1936-2625
  • [Journal-full-title] International journal of clinical and experimental pathology
  • [ISO-abbreviation] Int J Clin Exp Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2480552
  • [Keywords] NOTNLM ; Adenosquamous carcinoma / S100A2 / cholangiocarcinoma / extrahepatic bile duct / prognosis
  •  go-up   go-down


32. Pinheiro C, Longatto-Filho A, Ferreira L, Pereira SM, Etlinger D, Moreira MA, Jubé LF, Queiroz GS, Schmitt F, Baltazar F: Increasing expression of monocarboxylate transporters 1 and 4 along progression to invasive cervical carcinoma. Int J Gynecol Pathol; 2008 Oct;27(4):568-74
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increasing expression of monocarboxylate transporters 1 and 4 along progression to invasive cervical carcinoma.
  • The series analyzed included 29 chronic cervicitis, 30 low-grade squamous intraepithelial lesions, 32 high-grade squamous intraepithelial lesions, 49 squamous cell carcinomas, 51 adenocarcinomas, and 30 adenosquamous carcinomas of the uterine cervix.
  • We found a significant increase in MCT expression from preinvasive to invasive squamous lesions and from normal glandular epithelium to adenocarcinomas.
  • This is the first study evaluating the significance of MCT expression in lesions of the uterine cervix, including invasive carcinomas, and the results found herein led us to believe that these membrane proteins are involved in the progression to invasiveness in uterine cervix carcinoma.
  • [MeSH-major] Carcinoma / metabolism. Monocarboxylic Acid Transporters / biosynthesis. Muscle Proteins / biosynthesis. Symporters / biosynthesis. Uterine Cervical Neoplasms / metabolism
  • [MeSH-minor] Disease Progression. Female. Humans. Immunohistochemistry. Neoplasm Invasiveness. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18753962.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Monocarboxylic Acid Transporters; 0 / Muscle Proteins; 0 / SLC16A4 protein, human; 0 / Symporters; 0 / monocarboxylate transport protein 1
  •  go-up   go-down


33. Tiltman AJ: The pathology of cervical tumours. Best Pract Res Clin Obstet Gynaecol; 2005 Aug;19(4):485-500
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Carcinomas of the cervix may be categorized on morphological grounds into four main groups: squamous carcinomas; adenocarcinomas; neuro-endocrine tumours; and others including adenosquamous carcinomas.
  • Invasive squamous carcinomas and adenocarcinomas are preceded by cervical intra-epithelial neoplasia and cervical glandular intra-epithelial neoplasia, respectively.
  • Micro-invasive carcinomas with stromal invasion less than 3mm in depth have a minimal chance of lymph node metastasis.
  • Small cell carcinomas, large cell neuro-endocrine carcinomas and possibly adenoid cystic carcinomas are aggressive.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma, Squamous Cell / pathology. Neuroendocrine Tumors / pathology. Uterine Cervical Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16150389.001).
  • [ISSN] 1521-6934
  • [Journal-full-title] Best practice & research. Clinical obstetrics & gynaecology
  • [ISO-abbreviation] Best Pract Res Clin Obstet Gynaecol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Vascular Endothelial Growth Factor A
  • [Number-of-references] 94
  •  go-up   go-down


34. Hellberg D, Tot T, Stendahl U: Differences in expression of tumor markers between pre- and postmenopausal women with invasive cervical cancer. Anticancer Res; 2008 May-Jun;28(3B):1793-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • THE AIM of the present study was to investigate the differences in the expression of tumor markers in squamous cell and in adenomatous carcinomas in pre- and postmenopausal women, respectively.
  • Thirty-four tumors were adenomatous (n=31) or adenosquamous carcinomas (n=3), distributed between 13 premenopausal and 21 postmenopausal women.
  • The remaining 126 squamous cell carcinomas were diagnosed in 40 pre- and 86 postmenopausal women.
  • RESULTS: Expression of three tumor markers, p53 (>0% vs. 0%), p27 (> or =20% vs. <20%) and cyclooxygenase-2 (COX-2) (high intensity vs. moderate/none) differed significantly between pre- compared to postmenopausal women with squamous cell (p27; 54% vs. 72%, p=0.009) or adenomatous carcinomas (p53; 8% vs. 63%, p=0.006 and COX-2; 46% vs. 20%, p=0.03).
  • [MeSH-minor] Adult. Age Factors. Aged. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / pathology. Cyclin-Dependent Kinase Inhibitor p27 / biosynthesis. Cyclooxygenase 2 / biosynthesis. Female. Humans. Middle Aged. Neoplasm Invasiveness. Postmenopause / metabolism. Premenopause / metabolism. Tumor Suppressor Protein p53 / biosynthesis


35. Begum M, Robinson L, Sommers E, Bepler G: The impact of PET-based staging on survival of patients with stage I lung cancer. J Clin Oncol; 2009 May 20;27(15_suppl):7570

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Stage I, as defined by Mountain in 1997, includes tumors of any size located within one lobe of the lung without involvement of the parietal pleura, a distance of 2 cm or more from the carina, and no evidence for metastatic disease in any pulmonary, hilar, or mediastinal lymph node or distant site.
  • Description of pts: 638 women, 592 men; 11 African-American, 1215 Caucasian; 18 Hispanic, 1202 Non-Hispanic; age range 28.1-94.0 y, mean 68.9 y, median 69.9 y; 26 pneumonectomies, 243 segmentectomies or wedge resections; 699 adeno-, 15 adenosquamous, 325 squamous, 25 large cell, 57 neuroendocrine carcinomas; maximum tumor diameter range 0.1-25 cm, mean 2.9 cm, median 2.3 cm; 477 dead (survival 0.0-138.8 months), 753 alive (survival 0.1-144.4 months).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963355.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


36. Radaelli E, Arnold A, Papanikolaou A, Garcia-Fernandez RA, Mattiello S, Scanziani E, Cardiff RD: Mammary tumor phenotypes in wild-type aging female FVB/N mice with pituitary prolactinomas. Vet Pathol; 2009 Jul;46(4):736-45
Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Prolactin-secreting pituitary proliferations play a significant role in mouse mammary tumorigenesis generally producing adenosquamous carcinomas.
  • Compared with previous reports, prolactinoma-associated mammary tumors displayed a broader morphologic spectrum, including cases with the EMT phenotype.

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19276050.001).
  • [ISSN] 1544-2217
  • [Journal-full-title] Veterinary pathology
  • [ISO-abbreviation] Vet. Pathol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U01 CA141582; United States / NCI NIH HHS / CA / CA55909
  • [Publication-type] Case Reports; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


37. Tse GM, Tan PH, Chaiwun B, Putti TC, Lui PC, Tsang AK, Wong FC, Lo AW: p63 is useful in the diagnosis of mammary metaplastic carcinomas. Pathology; 2006 Feb;38(1):16-20
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] p63 is useful in the diagnosis of mammary metaplastic carcinomas.
  • AIMS: p63 has been recently reported to be expressed in sarcomatoid/metaplastic carcinoma of the breast, in addition to its role as a myoepithelial marker.
  • A large series of 34 metaplastic carcinomas, including cases with pure epithelial component (squamous cell and adenosquamous carcinomas), biphasic tumours with carcinomatous and sarcomatoid components and monophasic tumours with only spindle cell component, were evaluated for p63 expression with respect to the different cellular components.
  • METHODS: All of the metaplastic carcinomas were assessed for p63 and conventional epithelial and mesenchymal markers of AE1/3, CAM5.2 and vimentin by immunohistochemistry.
  • RESULTS: All of the different categories of metaplastic carcinomas showed similar clinico-pathological features (patient age, tumour size, nuclear grade, mitotic activity, lymph node status and hormonal receptor status).
  • For metaplastic carcinoma with epithelial component only, p63 was only expressed in the squamous cell component, but not the adenocarcinoma component.
  • Pure sarcomas and carcinomas were all negative for p63 staining by immunohistochemistry, thus rendering p63 staining highly specific for diagnosing metaplastic carcinoma.
  • CONCLUSIONS: Using p63 for diagnosis of metaplastic carcinoma gives a sensitivity of 65%, a specificity of 96%, a positive predictive value of 96%, and a negative predictive value of 66% and an accuracy of 78%.
  • p63 may be used as an adjunct marker in the diagnosis of metaplastic carcinoma.
  • [MeSH-minor] Adult. Aged. Anion Exchange Protein 1, Erythrocyte / analysis. Antiporters / analysis. Biomarkers / analysis. Biomarkers, Tumor / analysis. Carcinoma, Adenosquamous / chemistry. Carcinoma, Adenosquamous / diagnosis. Carcinoma, Adenosquamous / pathology. Carcinoma, Squamous Cell / chemistry. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / pathology. Female. Humans. Immunohistochemistry. Keratins / analysis. Middle Aged. Sarcoma / chemistry. Sarcoma / diagnosis. Sarcoma / pathology. Sensitivity and Specificity. Transcription Factors. Vimentin / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16484002.001).
  • [ISSN] 0031-3025
  • [Journal-full-title] Pathology
  • [ISO-abbreviation] Pathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anion Exchange Protein 1, Erythrocyte; 0 / Antiporters; 0 / Biomarkers; 0 / Biomarkers, Tumor; 0 / CAM 5.2 antigen; 0 / DNA-Binding Proteins; 0 / SLC4A3 protein, human; 0 / TP63 protein, human; 0 / Trans-Activators; 0 / Transcription Factors; 0 / Tumor Suppressor Proteins; 0 / Vimentin; 68238-35-7 / Keratins
  •  go-up   go-down


38. Andersson S, Hellström AC, Angström T, Stendahl U, Auer G, Wallin KL: The clinicopathologic significance of laminin-5 gamma2 chain expression in cervical squamous carcinoma and adenocarcinoma. Int J Gynecol Cancer; 2005 Nov-Dec;15(6):1065-72
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The clinicopathologic significance of laminin-5 gamma2 chain expression in cervical squamous carcinoma and adenocarcinoma.
  • Carcinoma of the uterine cervix is one of the most prevalent malignancies among women in developing countries and the third most common type worldwide.
  • Squamous cell carcinoma predominates in the cervix uteri, while adenocarcinoma and adenosquamous carcinomas represent about 10-15% of all cervical cancers.
  • The aim of our study was to investigate the expression of the laminin-5 gamma2 chain in primary malignancies of the cervix uteri and to focus on the clinicopathologic significance of the expression of the laminin-5 gamma2 chain in cervical squamous carcinoma and adenocarcinoma with respect to age and survival of the patients.
  • The study consisted of a total of 89 cases of invasive cervical cancer (54 squamous carcinomas and 35 adenocarcinomas).
  • The laminin-5 gamma2 chain was found in 80% of all the squamous carcinoma and in 66% of cervical adenocarcinoma.
  • The univariate analysis in squamous cell carcinoma showed that factors such as the stage of the disease and positive lymph nodes had an impact on the survival of the patients, whereas in the multivariate analysis, only age at diagnosis was an independent prognostic factor.
  • However, in cases with cervical adenocarcinoma, only the stage of the disease was an independent prognostic factor.
  • Our results indicate that the majority of the primary cervical tumors, especially squamous cell carcinoma, showed expression of laminin-5 gamma2 chain immunoreactivity.
  • Independent prognostic values for the survival of the patients were age and stage of the disease.
  • [MeSH-major] Adenocarcinoma / metabolism. Carcinoma, Squamous Cell / metabolism. Laminin / biosynthesis. Uterine Cervical Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16343183.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / LAMC2 protein, human; 0 / Laminin
  •  go-up   go-down


39. Massard G, Ducrocq X, Kochetkova EA, Porhanov VA, Riquet M: Sampling or node dissection for intraoperative staging of lung cancer: a multicentric cross-sectional study. Eur J Cardiothorac Surg; 2006 Jul;30(1):164-7
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PATIENTS AND METHODS: During a 4-month period, 208 consecutive patients (172 men, 36 women) without bulky disease underwent resection for primary lung cancer in three centers.
  • There were 108 squamous cell carcinomas, 621 adenocarcinomas, 18 bronchoalveolar carcinomas, 8 large cell carcinomas, 4 adenosquamous carcinomas and 8 neuroendocrine carcinomas.
  • N2 disease concerned a single node in 16, a single node station in 19, and multiple levels in 25.
  • Sampling adequately recognized N2 disease in 31 patients (52%).
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / secondary. Lung Neoplasms / pathology. Lymph Node Excision / methods

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Eur J Cardiothorac Surg. 2007 Jan;31(1):142-3; author reply 143-4 [17092737.001]
  • (PMID = 16725340.001).
  • [ISSN] 1010-7940
  • [Journal-full-title] European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  • [ISO-abbreviation] Eur J Cardiothorac Surg
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Multicenter Study
  • [Publication-country] Germany
  •  go-up   go-down


40. Yakut T, Schulten HJ, Demir A, Frank D, Danner B, Egeli U, Gebitekin C, Kahler E, Gunawan B, Urer N, Oztürk H, Füzesi L: Assessment of molecular events in squamous and non-squamous cell lung carcinoma. Lung Cancer; 2006 Dec;54(3):293-301
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessment of molecular events in squamous and non-squamous cell lung carcinoma.
  • Although considerable knowledge exists on the tumor biology of lung cancer, there is still a need to assess molecular events for the clinical management of the disease.
  • We studied the pattern of chromosomal imbalances in 45 non-small cell lung carcinomas (NSCLC) by comparative genomic hybridization (CGH) and correlated the results with clinicopathological features including immunohistochemical (IHC) expression of the epidermal growth factor receptor (EGFR).
  • Twenty-one tumors were squamous cell carcinomas (SCC) and 24 non-squamous cell lung carcinomas (NSCC) comprising 9 adenocarcinomas (ADC), 9 large cell carcinomas (LCC), 4 sarcomatoid carcinomas and 2 adenosquamous carcinomas.
  • In addition, +12p correlated significantly with disease progress with the exception of nodal involvement in NSCC as well as with disease progress, regardless of nodal involvement, in the entire series.
  • [MeSH-major] Carcinoma / genetics. Carcinoma, Squamous Cell / genetics. Genomic Instability. Lung Neoplasms / genetics


41. Xu ML, Liu Y, Zhong HH, Wu BQ: [Status and clinicopathologic implication of epidermal growth factor receptor mutation in non-small cell carcinoma of lung]. Zhonghua Bing Li Xue Za Zhi; 2007 Jul;36(7):453-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Status and clinicopathologic implication of epidermal growth factor receptor mutation in non-small cell carcinoma of lung].
  • OBJECTIVE: To investigate mutations of epidermal growth factor receptor (EGFR) exon 19 and 21 in non-small cell lung carcinoma and to explore their clinicopathological correlations.
  • METHOD: DNA was extracted from the excised tumor specimens of 66 non-small cell lung carcinoma patients by traditional phenol-chloroform and ethanol precipitation.
  • Mutations were more frequently observed in women (9/34, 26.5%) than in men (2/32, 6.3%), in adenocarcinomas (10/43, 23.3%) than squamous (0/13) and adenosquamous carcinomas (1/10).
  • Those with adenocarcinoma with bronchiolo-alveolar carcinoma (BAC) components had higher frequency of EGFR mutation (6/11) than those without non-BAC element (4/32, 12.5%).
  • [MeSH-major] Amino Acid Substitution. Carcinoma, Non-Small-Cell Lung / genetics. Gene Deletion. Lung Neoplasms / genetics. Receptor, Epidermal Growth Factor / genetics
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / pathology. Adult. Aged. DNA Mutational Analysis. DNA, Neoplasm / genetics. Exons. Female. Humans. Male. Middle Aged. Mutation. Sex Factors

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17845757.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / DNA, Neoplasm; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


42. Baker AC, Eltoum I, Curry RO, Stockard CR, Manne U, Grizzle WE, Chhieng D: Mucinous expression in benign and neoplastic glandular lesions of the uterine cervix. Arch Pathol Lab Med; 2006 Oct;130(10):1510-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucinous expression in benign and neoplastic glandular lesions of the uterine cervix.
  • CONTEXT: Mucins are glycoproteins produced by both normal and neoplastic glandular epithelial cells including endocervix.
  • OBJECTIVE: To determine the expression of mucins in uterine cervical glandular lesions and whether mucin expression correlates with the nature and origin of the glandular lesions.
  • DESIGN: Antibodies to MUC1, MUC2, MUC4, and MUC5AC were applied on 52 cases including 14 endocervical adenocarcinomas (including 4 adenosquamous carcinomas), 9 endometrial carcinomas (8 endometrioid adenocarcinomas and 1 adenosquamous carcinoma), 8 adenocarcinoma in situ (AIS), 2 glandular dysplasias, 6 tubal metaplasias, 10 microglandular hyperplasias, and 3 normal endocervix.
  • Almost all endocervical AIS and carcinomas and all endometrial adenocarcinomas expressed MUC1; the exceptions were 2 cases of endocervical adenocarcinoma and 1 case of adenosquamous carcinoma of the endocervix.
  • These results suggest that mucin staining may potentially be helpful in differentiating various uterine cervical glandular lesions.
  • [MeSH-major] Adenocarcinoma / metabolism. Mucins / metabolism. Uterine Cervical Diseases / metabolism. Uterine Cervical Neoplasms / metabolism
  • [MeSH-minor] Carcinoma / metabolism. Endometrial Neoplasms / metabolism. Female. Humans. Immunohistochemistry / methods. Mucin 5AC. Mucin-1 / metabolism. Mucin-2. Mucin-4. Staining and Labeling

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Cervix Disorders.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17090193.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / MUC2 protein, human; 0 / MUC4 protein, human; 0 / MUC5AC protein, human; 0 / Mucin 5AC; 0 / Mucin-1; 0 / Mucin-2; 0 / Mucin-4; 0 / Mucins
  •  go-up   go-down


43. Cakir E, Demirag E, Aydin M, Unsal E: Clinicopathologic features and prognostic significance of lung tumours with mixed histologic patterns. Acta Chir Belg; 2009 Jul-Aug;109(4):489-93
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathologic features and prognostic significance of lung tumours with mixed histologic patterns.
  • Lung tumours with a mixed histologic pattern are rare.
  • We evaluated the clinicopathologic features and prognosis of lung tumours with mixed histology and compared them with the tumours which have single histology.
  • The study group consisted of 39 patients with a mixed histologic pattern and a control group consisted of 41 patients with a single histology on the consecutive surgical specimens.
  • In the study group three types of tumour were identified: adenosquamous carcinoma, combined neuro-endocrine tumours and biphasic tumours.
  • The combined neuro-endocrine tumours were further divided into small cell carcinoma (SCLC)+non-neuro-endocrine carcinoma (NNEC), SCLC+large cell neuro-endocrine carcinoma (LCNEC) and LCNEC +NNEC.
  • Among adenosquamous carcinomas advanced stage (IIIa or IIIb) (p = 0.004), vascular invasion (p = 0.04) and parietal pleural involvement (p = 0.012) was significantly more evident than in the single histology group.
  • Two- year survival rates were 60% for the single histology group, 39% for the adenosquamous group and 25% for the combined neuro-endocrine tumour group (p = 0.0002).
  • Tumours with mixed histology are rarely seen in the lung.
  • Among these tumours adenosquamous carcinoma and combined neuro-endocrine tumours present more aggressive clinico-pathologic behaviour than tumors with a single histology.
  • [MeSH-major] Carcinoma, Bronchogenic / pathology. Lung Neoplasms / pathology
  • [MeSH-minor] Aged. Carcinoma, Adenosquamous / mortality. Carcinoma, Adenosquamous / pathology. Carcinoma, Adenosquamous / surgery. Carcinoma, Neuroendocrine / mortality. Carcinoma, Neuroendocrine / pathology. Carcinoma, Neuroendocrine / surgery. Female. Humans. Male. Middle Aged. Pneumonectomy. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19803261.001).
  • [ISSN] 0001-5458
  • [Journal-full-title] Acta chirurgica Belgica
  • [ISO-abbreviation] Acta Chir. Belg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Belgium
  •  go-up   go-down


44. Mayun AA, Nggada HA, Audu BM, Pindiga UH, Khalil MI, Musa AB: Histopathological analysis of non-squamous cell malignancies of the uterine cervix in Maiduguri, Nigeria. Afr J Med Med Sci; 2008 Dec;37(4):369-73
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histopathological analysis of non-squamous cell malignancies of the uterine cervix in Maiduguri, Nigeria.
  • Carcinoma of the uterine cervix is the most common gynaecological malignancy in the developing world despite being largely preventable.
  • The non-squamous cancers of the cervix have not been properly documented in our setting.
  • This study is aimed at reviewing the histological types ofnon-squamous cell cancers of the uterine cervix in relation to the age of presentation, and to analyze some of the histopathological features of adenocarcinomas.
  • Of these, 432(88.0%) cases were squamous cell carcinomas while 59(12.0%) were non-squamous cell malignancies.
  • Out of the 59 non-squamous cervical cancers, 42(71.2%) were endocervical-type adenocarcinomas, while serous papillary, clear cell, and adenosquamous carcinomas comprised 2(3.4%) cases each.
  • Adenocarcinomas are the most common non-squamous malignancies of the cervix and their age of presentation was similar to that of their squamous cell counterpart.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma, Adenosquamous / pathology. Uterine Cervical Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19301715.001).
  • [ISSN] 0309-3913
  • [Journal-full-title] African journal of medicine and medical sciences
  • [ISO-abbreviation] Afr J Med Med Sci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Nigeria
  •  go-up   go-down


45. Satoh Y, Hoshi R, Ishikawa Y, Horai T, Okumura S, Nakagawa K: Recurrence patterns in patients with early stage non-small cell lung cancers undergoing positive pleural lavage cytology. Ann Thorac Surg; 2007 Jan;83(1):197-202
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrence patterns in patients with early stage non-small cell lung cancers undergoing positive pleural lavage cytology.
  • However, there is some controversy whether radical surgery is warranted based on the positive PLC findings with stage I non-small cell lung cancers (NSCLCs).
  • RESULTS: PLC findings were positive in 41 patients (4.8%), rates being most frequent with adenosquamous carcinomas and adenocarcinomas.
  • In the positive group, distant metastases (72%) and pleural recurrence (25%) (p = 0.0011) were often observed, and the survival rate was significantly poorer (p < 0.002), even for patients with stage I disease (p = 0.009).
  • CONCLUSIONS: PLC is a distinct prognostic factor for early stage lung carcinomas.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / pathology. Lung Neoplasms / pathology. Neoplasm Recurrence, Local / pathology. Pleura / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Thorac Surg. 2007 Jan;83(1):202-3 [17184662.001]
  • (PMID = 17184661.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  •  go-up   go-down


46. Takac I: Transvaginal ultrasonography with and without saline infusion in assessment of myometrial invasion of endometrial cancer. J Ultrasound Med; 2007 Jul;26(7):949-55; quiz 956-7
Hazardous Substances Data Bank. SODIUM CHLORIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The median thickness of malignant endometria was 17 +/- 9 mm (range, 2-51 mm).
  • The specimens consisted of 40 endometrioid adenocarcinomas, 2 serous papillary carcinomas, 5 clear cell adenocarcinomas, 2 adenosquamous carcinomas, 3 mixed types, and 1 undifferentiated carcinoma.
  • [MeSH-minor] Adenocarcinoma, Clear Cell / pathology. Adenocarcinoma, Clear Cell / ultrasonography. Administration, Intravaginal. Aged. Carcinoma / pathology. Carcinoma / ultrasonography. Carcinoma, Endometrioid / pathology. Carcinoma, Endometrioid / ultrasonography. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / ultrasonography. Cystadenocarcinoma, Papillary / pathology. Cystadenocarcinoma, Papillary / ultrasonography. Endometrium / pathology. Endometrium / ultrasonography. Female. Humans. Middle Aged. Neoplasm Invasiveness. Postmenopause. Preoperative Care. Reproducibility of Results. Sensitivity and Specificity. Sodium Chloride / administration & dosage

  • Genetic Alliance. consumer health - Endometrial cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17592058.001).
  • [ISSN] 0278-4297
  • [Journal-full-title] Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine
  • [ISO-abbreviation] J Ultrasound Med
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 451W47IQ8X / Sodium Chloride
  •  go-up   go-down


47. Pardo J, Martinez-Peñuela AM, Sola JJ, Panizo A, Gúrpide A, Martinez-Peñuela JM, Lozano MD: Large cell carcinoma of the lung: an endangered species? Appl Immunohistochem Mol Morphol; 2009 Oct;17(5):383-92
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Large cell carcinoma of the lung: an endangered species?
  • This study aims to evaluate large cell carcinomas (LCC) of the lung with a panel of immunohistochemical markers in an attempt to identify tumors belonging to other categories.
  • The tumors were 82 (81.3%) classic LCC, 7 (6.9%) neuroendocrine LCC, 6 (5.9%) lymphoepithelioma-like LCC, 3 (2.9%) basaloid LCC, 2 (2%) clear cell LCC, and 1 (1%) LCC with rhabdoid phenotype.
  • Characteristic classic LCC immunophenotype was loss of staining with CK5/6, CK14 positive in most squamous cell carcinoma (SCC), lack of MOC 31 positive in most adenocarcinomas, and positive immunoreactivity to EGFR, PDGFR-alpha and c-kit.
  • 16 (19.5%) of 82 classic LCC correspond to undifferentiated adenosquamous carcinomas, since they displayed conflicting immunostaining for markers of both SCC and adenocarcinomas.
  • The use of 7 immunohistochemical markers, consisting of TTF-1, CK7, CK19, p63, 34betaE12, thrombomodulin, and CD44v6, markedly reduces dramatically to less than 10%, the number of classic LCC by readily identifying cases of poorly differentiated SCCs, adenosquamous carcinoma and adenocarcinomas.

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19444077.001).
  • [ISSN] 1533-4058
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal
  •  go-up   go-down


48. Yeasmin S, Nakayama K, Ishibashi M, Katagiri A, Iida K, Purwana IN, Nakayama N, Miyazaki K: Expression of the bric-a-brac tramtrack broad complex protein NAC-1 in cervical carcinomas seems to correlate with poorer prognosis. Clin Cancer Res; 2008 Mar 15;14(6):1686-91
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of the bric-a-brac tramtrack broad complex protein NAC-1 in cervical carcinomas seems to correlate with poorer prognosis.
  • PURPOSE: Recent studies have suggested a novel oncogenic role of a bric-a-brac tramtrack broad complex (also known as POZ) domain gene, NAC-1, in ovarian carcinomas.
  • The aim of this study was to clarify the functional role of NAC-1 in human cervical carcinomas.
  • NAC-1 gene knockdown using small interfering RNA and a NAC-1 gene transfection system were used to asses NAC-1 function in cervical cancer in vivo.
  • RESULTS: Immunohistochemical and gene expression analysis revealed that NAC-1 is significantly overexpressed in cervical adenocarcinomas and adenosquamous carcinomas compared with squamous cell carcinomas.
  • Patients with squamous cell carcinomas positive for NAC-1 expression who received radiotherapy had significantly shorter overall survival than peers whose tumors did not express NAC-1, and multivariate analysis showed that NAC-1 expression was an independent prognostic factor for overall survival after radiotherapy.
  • Overexpressions of the NAC-1 gene stimulated cell proliferation in cervical carcinoma cells of the TCS, CaSki, and HeLa P3 lines, which do not have endogenous NAC-1 expression.
  • NAC-1 gene knockdown inhibited cell growth and induced apoptosis in HeLa, HeLa TG, and ME180 cells, all of which overexpressed NAC-1.
  • CONCLUSIONS: Our findings suggest that NAC-1 may play an important role in cervical carcinomas; moreover, these findings provide a rationale for future development of NAC-1-based therapy for cervical carcinomas that overexpress this candidate oncogene.
  • [MeSH-major] Adenocarcinoma / diagnosis. Neoplasm Proteins / metabolism. Repressor Proteins / metabolism. Uterine Cervical Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Apoptosis / drug effects. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / genetics. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / radiotherapy. Female. Gene Expression Regulation, Neoplastic. HeLa Cells. Humans. Middle Aged. Multiprotein Complexes / genetics. Multiprotein Complexes / metabolism. Prognosis. RNA, Small Interfering / pharmacology. Survival Analysis. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18347169.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Multiprotein Complexes; 0 / NACC1 protein, human; 0 / Neoplasm Proteins; 0 / RNA, Small Interfering; 0 / Repressor Proteins
  •  go-up   go-down


49. Attoh S, Asmah R, Wiredu EK, Gyasi R, Tettey Y: Human papilloma virus genotypes in Ghanaian women with cervical carcinoma. East Afr Med J; 2010 Aug;87(8):345-9
MedlinePlus Health Information. consumer health - Cervical Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human papilloma virus genotypes in Ghanaian women with cervical carcinoma.
  • HPV type 18 was more relatively frequent in adenocarcinomas and adenosquamous carcinomas than in squamous cell carcinomas.
  • This is contrary to the worldwide prevalence where HPV 16 is the most common type associated with invasive cervical carcinoma.
  • [MeSH-major] Adenocarcinoma / virology. Carcinoma, Squamous Cell / virology. Papillomaviridae / genetics. Uterine Cervical Neoplasms / virology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 23451558.001).
  • [ISSN] 0012-835X
  • [Journal-full-title] East African medical journal
  • [ISO-abbreviation] East Afr Med J
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Kenya
  •  go-up   go-down


50. Igarashi M, Yoshida M, Watanabe M, Yamada T, Sakurai T, Endo Y, Miyajima N, Maekawa A, Oikawa T, Sugano S, Nakae D: Involvement of mutation-based inhibition of beta-catenin phosphorylation at Ser33 in the malignant progression of lung (pre)neoplastic lesions induced by N-nitrosobis(2-hydroxypropyl)amine in male Fischer 344 rats. Lung; 2007 Sep-Oct;185(5):271-278
Hazardous Substances Data Bank. L-SERINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Involvement of mutation-based inhibition of beta-catenin phosphorylation at Ser33 in the malignant progression of lung (pre)neoplastic lesions induced by N-nitrosobis(2-hydroxypropyl)amine in male Fischer 344 rats.
  • Histopathologically, 69 of 75 rats demonstrated multiple lung (pre)neoplastic lesions, classified into 27 slight and 33 advanced hyperplasias (preneoplasms) and 61 neoplasms, including adenomas, adenocarcinomas, and adenosquamous carcinomas.
  • Immunohistochemical analysis showed beta-catenin protein expression to be increased and its localization changed from the cell membrane to the cytoplasm and finally the nuclei with advancing malignancy of the lung lesions.
  • These phenomena might contribute to the malignant progression of the lung (pre)neoplastic lesions, which start from the relatively early stage in lung carcinogenesis.
  • [MeSH-major] Cell Transformation, Neoplastic / genetics. Gene Expression Regulation, Neoplastic. Lung Neoplasms / genetics. Mutation. Precancerous Conditions / genetics. beta Catenin / genetics
  • [MeSH-minor] Active Transport, Cell Nucleus. Animals. Cell Membrane / metabolism. Cell Nucleus / metabolism. Cytoplasm / metabolism. DNA Mutational Analysis. Disease Models, Animal. Male. Nitrosamines. Phosphorylation. Rats. Rats, Inbred F344. Serine / metabolism

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17639448.001).
  • [ISSN] 0341-2040
  • [Journal-full-title] Lung
  • [ISO-abbreviation] Lung
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ctnnb1 protein, rat; 0 / Nitrosamines; 0 / beta Catenin; 452VLY9402 / Serine; 4J072HB2ND / diisopropanolnitrosamine
  •  go-up   go-down


51. Gingelmaier A, Gutsche S, Mylonas I, Shabani N, Kuhn C, Kunze S, Jeschke U, Friese K: Expression of HPV, steroid receptors (ERalpha, ERbeta, PR-A and PR-B) and inhibin/activin subunits (alpha, betaA and betaB) in adenosquamous endometrial carcinoma. Anticancer Res; 2007 Jul-Aug;27(4A):2011-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of HPV, steroid receptors (ERalpha, ERbeta, PR-A and PR-B) and inhibin/activin subunits (alpha, betaA and betaB) in adenosquamous endometrial carcinoma.
  • AIM: The aim of the study was to determine possible pathogenetic factors and molecules which may be used as tumor markers of adenosquamous endometrial carcinoma.
  • MATERIALS AND METHODS: Eight adenosquamous endometrial carcinomas were immunohistochemically tested with specific monoclonal antibodies for HPV (polyclonal anti-HPV and monoclonal anti-HPV 18), estrogen receptors ER-alpha and ER-beta, progesterone receptors PR-A and PR-B and the inhibin/activin subunits inhibin-alpha, -betaA and -betaB.
  • RESULTS: HPV 18 and the polyclonal HPV antibody was detected in all adenosquamous endometrial carcinomas, both in the endometrioid (n = 7/8) and squamous (n = 8/8) parts of the tumor.
  • Neither ER-alpha or ER-beta were detectable in any tumor, in contrast to PR-A and PR-B which were detected in about half of these tumors (PR-A: n = 5/8 and PR-B: n = 2/8).
  • Inhibin-alpha and -betaB were not detected, while inhibin-betaA was expressed in all adenosquamous carcinomas.
  • CONCLUSION: The carcinogenesis of adenosquamous endometrial carcinomas was associated with HPV infection.
  • Adenosquamous endometrial carcinomas seem not to be controlled by estrogens.
  • The absence of the expression of the inhibin-alpha subunit suggests a tumor-suppressive function in adenosquamous endometrial tumors.
  • The other inhibin subunit, inhibin-betaA, was expressed in all adenosquamous tumors.
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma, Adenosquamous / metabolism. Carcinoma, Adenosquamous / virology. Endometrial Neoplasms / metabolism. Endometrial Neoplasms / virology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17649814.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antigens, Viral; 0 / Biomarkers, Tumor; 0 / Receptors, Steroid; 104625-48-1 / Activins; 57285-09-3 / Inhibins
  •  go-up   go-down


52. Wang LJ, Greaves WO, Sabo E, Noble L, Tavares R, Ng T, DeLellis RA, Resnick MB: GCDFP-15 positive and TTF-1 negative primary lung neoplasms: a tissue microarray study of 381 primary lung tumors. Appl Immunohistochem Mol Morphol; 2009 Dec;17(6):505-11
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Gross cystic disease fluid protein (GCDFP-15) is currently used as an immunohistochemical marker of breast cancer, whereas thyroid transcription factor (TTF-1) is commonly used as a marker of primary lung neoplasms.
  • Traditionally, a GCDFP-15+/TTF-1- immunohistochemical profile in lung tumors has been considered as highly suggestive of metastatic carcinoma of the breast.
  • Here, we investigated the expression of GCDFP-15 and TTF-1 on a tissue microarray consisting of 381 primary lung carcinomas.
  • Seventeen tumors (4.5%) were positive for GCDFP-15, including 11 of 186 (5.9%) adenocarcinomas, 1 of 97 (1%) squamous cell carcinomas, 1 of 23 (4.3%) carcinoid tumors, 2 of 47 (4.3%) large cell carcinomas, and 2 of 17 (11.8%) adenosquamous carcinomas.
  • Thus a GCDFP-15 positive/TTF-1 negative phenotype may not be indicative of metastatic breast carcinoma in every case.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19620839.001).
  • [ISSN] 1533-4058
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Carrier Proteins; 0 / DNA-Binding Proteins; 0 / Glycoproteins; 0 / PIP protein, human; 0 / TTF1 protein, human
  •  go-up   go-down


53. Zhang H, Zhao Q, Chen Y, Wang Y, Gao S, Mao Y, Li M, Peng A, He D, Xiao X: Selective expression of S100A7 in lung squamous cell carcinomas and large cell carcinomas but not in adenocarcinomas and small cell carcinomas. Thorax; 2008 Apr;63(4):352-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Selective expression of S100A7 in lung squamous cell carcinomas and large cell carcinomas but not in adenocarcinomas and small cell carcinomas.
  • The specific expression of this protein and its cellular distribution were investigated in 145 paraffin embedded lung cancer samples, six benign lung disease and 21 normal lung tissues by immunohistochemistry.
  • RESULTS: Specific expression of both S100A7 mRNA and protein was found in squamous cell carcinomas, adenosquamous carcinomas and large cell lung carcinomas, whereas neither was detected in adenocarcinomas or paired non-cancerous lung tissues.
  • Further immunohistochemical analysis identified positive staining of S100A7 only in squamous cell carcinomas and large cell lung carcinomas, but not in other subtypes of lung cancer and normal lung tissues.
  • Our most important finding is that elevated S100A7 protein could be detected in the sera of patients with squamous cell carcinomas.
  • CONCLUSION: S100A7 was only expressed in squamous cell carcinomas and large cell lung carcinomas and an increase in the level of S100A7 protein in serum may serve as a potential marker for lung cancer diagnosis.
  • [MeSH-major] Adenocarcinoma / diagnosis. Calcium-Binding Proteins / metabolism. Carcinoma, Large Cell / diagnosis. Carcinoma, Squamous Cell / diagnosis. Lung Neoplasms / diagnosis. Neoplasm Proteins / metabolism

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18364444.001).
  • [ISSN] 1468-3296
  • [Journal-full-title] Thorax
  • [ISO-abbreviation] Thorax
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Calcium-Binding Proteins; 0 / Neoplasm Proteins; 0 / S100 Proteins; 0 / S100A7 protein, human
  •  go-up   go-down


54. Achcar Rde O, Nikiforova MN, Dacic S, Nicholson AG, Yousem SA: Mammalian mastermind like 2 11q21 gene rearrangement in bronchopulmonary mucoepidermoid carcinoma. Hum Pathol; 2009 Jun;40(6):854-60
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mammalian mastermind like 2 11q21 gene rearrangement in bronchopulmonary mucoepidermoid carcinoma.
  • The translocation t(11;19)(q21;p13) results in the gene fusion of mucoepidermoid carcinoma translocated 1-mammalian mastermind like 2 genes that is the major chromosomal abnormality observed in mucoepidermoid carcinomas of salivary glands but has not been studied in bronchopulmonary mucoepidermoid carcinoma.
  • To investigate the importance of the mammalian mastermind like 2 gene rearrangement and mucoepidermoid carcinoma translocated 1-mammalian mastermind like 2 fusion gene in bronchopulmonary mucoepidermoid carcinoma tumorigenesis and its differential diagnosis with primary pulmonary non-small-cell carcinomas, we evaluated the presence of the mammalian mastermind like 2 gene rearrangement and the mucoepidermoid carcinoma translocated 1-mammalian mastermind like 2 fusion in formalin-fixed, paraffin-embedded tissue sections from 17 adult bronchopulmonary mucoepidermoid carcinoma, 16 adenosquamous carcinomas, 24 squamous cell carcinomas, and 41 primary adenocarcinomas by fluorescence in situ hybridization and reverse transcriptase polymerase chain reaction.
  • We detected mammalian mastermind like 2 gene rearrangement by fluorescence in situ hybridization analysis in 13 (77%) of 17 bronchopulmonary mucoepidermoid carcinoma cases (10 of 10 being low grade and 3 of 7 being high grade).
  • Reverse transcriptase polymerase chain reaction analysis confirmed positive fluorescence in situ hybridization results in 6 (43%) of 14 mucoepidermoid carcinoma cases.
  • None of the squamous, adenosquamous, or adenocarcinoma cases revealed the mammalian mastermind like 2 gene rearrangement by fluorescence in situ hybridization, and the mucoepidermoid carcinoma translocated 1-mammalian mastermind like 2 fusion product by reverse transcriptase polymerase chain reaction was not identified specifically in our adenosquamous carcinoma cases.
  • In conclusion, our study demonstrates that mammalian mastermind like 2 gene rearrangement and mucoepidermoid carcinoma translocated 1-mammalian mastermind like 2 fusion product can be detected by fluorescence in situ hybridization and reverse transcriptase polymerase chain reaction analysis performed on low- and high-grade primary bronchopulmonary mucoepidermoid carcinoma and can be used to help discriminate low- and high-grade mucoepidermoid carcinoma from adenocarcinoma, adenosquamous carcinoma, and squamous cell carcinoma mimics in histologically challenging cases.
  • [MeSH-major] Bronchial Neoplasms / genetics. Carcinoma, Mucoepidermoid / genetics. DNA-Binding Proteins / genetics. Lung Neoplasms / genetics. Nuclear Proteins / genetics. Oncogene Proteins, Fusion / genetics. Transcription Factors / genetics
  • [MeSH-minor] Adenosarcoma / genetics. Adenosarcoma / pathology. Adult. Aged. Aged, 80 and over. Carcinoma, Adenosquamous / genetics. Carcinoma, Adenosquamous / pathology. Carcinoma, Squamous Cell / genetics. Carcinoma, Squamous Cell / pathology. Female. Gene Fusion. Gene Rearrangement. Humans. In Situ Hybridization, Fluorescence. Male. Middle Aged. Reverse Transcriptase Polymerase Chain Reaction. Translocation, Genetic

  • Genetic Alliance. consumer health - Mucoepidermoid carcinoma.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19269006.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CRTC1 protein, human; 0 / DNA-Binding Proteins; 0 / MAML2 protein, human; 0 / MECT1-MAML2 fusion protein, human; 0 / Nuclear Proteins; 0 / Oncogene Proteins, Fusion; 0 / Transcription Factors
  •  go-up   go-down


55. Rodríguez-Sastre MA, González-Maya L, Delgado R, Lizano M, Tsubaki G, Mohar A, García-Carrancá A: Abnormal distribution of E-cadherin and beta-catenin in different histologic types of cancer of the uterine cervix. Gynecol Oncol; 2005 May;97(2):330-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: We performed an immunochemical staining analysis of the cellular distribution of beta-catenin and E-cadherin proteins in biopsy samples from 20 normal exocervical squamous epithelium, 43 premalignant lesions, and a large series of 126 invasive tumors of different histologic types that included 68 squamous carcinomas, 31 adenosquamous carcinomas, and 27 adenocarcinomas.
  • Similarly, we found that E-cadherin exhibit a significant abnormal distribution in the cytoplasm of 58% of premalignant lesions (P < 0.05) and in more than 71% of squamous carcinoma and adenosquamous carcinoma when compared with normal tissue (P < 0.05).
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Adult. Aged. Aged, 80 and over. Carcinoma, Adenosquamous / metabolism. Carcinoma, Adenosquamous / pathology. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / pathology. Cervix Uteri / metabolism. Female. Humans. Immunohistochemistry. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Precancerous Conditions / metabolism. Precancerous Conditions / pathology. beta Catenin

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15863126.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CTNNB1 protein, human; 0 / Cadherins; 0 / Cytoskeletal Proteins; 0 / Trans-Activators; 0 / beta Catenin
  •  go-up   go-down


56. Rea F, Marulli G, Schiavon M, Zuin A, Hamad AM, Rizzardi G, Perissinotto E, Sartori F: A quarter of a century experience with sleeve lobectomy for non-small cell lung cancer. Eur J Cardiothorac Surg; 2008 Sep;34(3):488-92; discussion 492
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A quarter of a century experience with sleeve lobectomy for non-small cell lung cancer.
  • OBJECTIVE: Sleeve lobectomy represents an effective and widely accepted surgical therapy for non-small cell lung carcinoma (NSCLC).
  • Pathology revealed 167 (83.9%) squamous carcinomas, 23 (11.6%) adenocarcinomas, 7 (3.5%) large cell and 2 (1%) adenosquamous carcinomas.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / surgery. Lung Neoplasms / surgery. Pneumonectomy / methods

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18579399.001).
  • [ISSN] 1873-734X
  • [Journal-full-title] European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  • [ISO-abbreviation] Eur J Cardiothorac Surg
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


57. Wong DW, Leung EL, So KK, Tam IY, Sihoe AD, Cheng LC, Ho KK, Au JS, Chung LP, Pik Wong M, University of Hong Kong Lung Cancer Study Group: The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS. Cancer; 2009 Apr 15;115(8):1723-33
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase (EML4-ALK) fusion gene resulting from the chromosome inversion inv(2)(p21;p23) recently was identified in nonsmall cell lung cancer (NSCLC).
  • METHODS: EML4-ALK was investigated in 266 resected primary NSCLC, including adenocarcinomas (AD), lymphoepithelioma-like carcinomas, squamous cell carcinomas, mucoepidermoid carcinomas, and adenosquamous carcinomas, by reverse transcriptase-polymerase chain reaction and was verified by sequencing.
  • There were 11 ADs and 2 unusual carcinomas with mixed squamous and glandular components.
  • Immunohistochemistry demonstrated diffuse ALK fusion proteins in the tumor cell cytoplasm.
  • Patients who had EML4-ALK-positive AD had a younger median age (P = .018) compared with patients who did not have the fusion gene.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / genetics. Genes, ras. Lung Neoplasms / genetics. Oncogene Proteins, Fusion / genetics. Receptor, Epidermal Growth Factor / genetics. Smoking


58. Tong SY, Lee YS, Park JS, Namkoong SE: Human papillomavirus genotype as a prognostic factor in carcinoma of the uterine cervix. Int J Gynecol Cancer; 2007 Nov-Dec;17(6):1307-13
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human papillomavirus genotype as a prognostic factor in carcinoma of the uterine cervix.
  • The clinical implications of specific human papillomavirus (HPV) types in invasive cervical carcinomas are only now beginning to be appreciated.
  • The objective of this study was to determine the clinical implications and prognostic value of the HPV genotype in cervical carcinomas.
  • The HPV-16-related types were detected more frequently in patients with squamous cell carcinomas, whereas the HPV-18-related types were more prevalent in cases of adenocarcinomas and adenosquamous carcinomas (P < 0.05).
  • We conclude that neither the presence nor type of HPV DNA bears any prognostic significance in cases of cervical carcinoma.
  • [MeSH-major] Carcinoma / virology. Papillomaviridae / genetics. Papillomavirus Infections / complications. Uterine Cervical Neoplasms / virology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17425678.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


59. Puntambekar SP, Palep RJ, Puntambekar SS, Wagh GN, Patil AM, Rayate NV, Agarwal GA: Laparoscopic total radical hysterectomy by the Pune technique: our experience of 248 cases. J Minim Invasive Gynecol; 2007 Nov-Dec;14(6):682-9
MedlinePlus Health Information. consumer health - Hysterectomy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MEASUREMENTS AND MAIN RESULTS: Histopathologically, there were 183 (73%) cases of squamous carcinoma, 52 (20%) adenocarcinomas, and 13 (5%) adenosquamous carcinomas.
  • [MeSH-major] Carcinoma / surgery. Hysterectomy / methods. Laparoscopy / methods. Uterine Cervical Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Minim Invasive Gynecol. 2008 Mar-Apr;15(2):254-5; author reply 255 [18313003.001]
  • [CommentIn] J Minim Invasive Gynecol. 2008 Jul-Aug;15(4):518 [18602057.001]
  • [CommentIn] J Minim Invasive Gynecol. 2008 May-Jun;15(3):387-8; author reply 388 [18439520.001]
  • (PMID = 17980327.001).
  • [ISSN] 1553-4650
  • [Journal-full-title] Journal of minimally invasive gynecology
  • [ISO-abbreviation] J Minim Invasive Gynecol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


60. Kang S, Kim MH, Park IA, Kim JW, Park NH, Kang D, Yoo KY, Kang SB, Lee HP, Song YS: Elevation of cyclooxygenase-2 is related to lymph node metastasis in adenocarcinoma of uterine cervix. Cancer Lett; 2006 Jun 18;237(2):305-11
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Elevation of cyclooxygenase-2 is related to lymph node metastasis in adenocarcinoma of uterine cervix.
  • In a previous study, we demonstrated that elevation of COX-2 is significantly associated with lymph node metastasis in squamous cell carcinoma (SCC) of cervix.
  • The main objective of this study is to characterize the relationship between elevation of COX-2 and its possible clinical role in adenocarcinoma (AC) of cervix.
  • Using immunohistochemistry, we examined COX-2 expression levels in 84 patients with AC of uterine cervix [71 ACs, 13 adenosquamous carcinomas (ASCs)].
  • [MeSH-major] Adenocarcinoma / pathology. Cyclooxygenase 2 / biosynthesis. Gene Expression Regulation, Enzymologic. Gene Expression Regulation, Neoplastic. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Adult. Antigens, Neoplasm. Antineoplastic Agents / pharmacology. Disease Progression. Female. Humans. Lymphatic Metastasis. Middle Aged


61. Lee JW, Soung YH, Kim SY, Nam SW, Park WS, Wang YP, Jo KH, Moon SW, Song SY, Lee JY, Yoo NJ, Lee SH: ERBB2 kinase domain mutation in the lung squamous cell carcinoma. Cancer Lett; 2006 Jun 8;237(1):89-94
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ERBB2 kinase domain mutation in the lung squamous cell carcinoma.
  • The purpose of this was to see whether the ERBB2 kinase domain is mutated in other lung cancer types besides the adenocarcinoma.
  • Here, we performed mutational analysis of the ERBB2 kinase domain by polymerase chain reaction-single strand conformation polymorphism assay in 114 non-adenocarcinoma type non-small cell lung cancers (NSCLCs) tissue samples, including 100 squamous cell carcinomas, three adenosquamous carcinomas and 11 large cell carcinomas.
  • We detected the ERBB2 kinase domain mutation in one squamous cell carcinoma (1.0%).
  • We simultaneously analyzed the somatic mutations of EGFR, K-RAS, PIK3CA and BRAF genes in the squamous cell carcinoma with the ERBB2 mutation, and found that the tumor did not harbor any EGFR or ERBB2 or K-RAS or PIK3CA or BRAF gene mutation, either.
  • This study demonstrated that in addition to lung adenocarcinoma ERBB2 kinase domain mutation could occur in lung squamous cell carcinomas, and suggested that alterations of ERBB2-mediated signaling pathway by ERBB2 mutations may occasionally contribute to the development of lung squamous cell carcinomas.
  • [MeSH-major] Carcinoma, Adenosquamous / genetics. Carcinoma, Large Cell / genetics. Carcinoma, Non-Small-Cell Lung / genetics. Carcinoma, Squamous Cell / genetics. Gene Expression Regulation, Neoplastic. Lung Neoplasms / genetics. Receptor, ErbB-2 / genetics


62. Hammouda D, Muñoz N, Herrero R, Arslan A, Bouhadef A, Oublil M, Djedeat B, Fontanière B, Snijders P, Meijer C, Franceschi S: Cervical carcinoma in Algiers, Algeria: human papillomavirus and lifestyle risk factors. Int J Cancer; 2005 Jan 20;113(3):483-9
MedlinePlus Health Information. consumer health - Cervical Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cervical carcinoma in Algiers, Algeria: human papillomavirus and lifestyle risk factors.
  • A total of 198 cervical carcinoma (CC) cases (including 15 adeno- and adenosquamous carcinomas) and 202 age-matched control women were included.
  • [MeSH-major] Adenocarcinoma. Carcinoma, Adenosquamous. Papillomaviridae / isolation & purification. Papillomavirus Infections / epidemiology. Uterine Cervical Neoplasms

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15455386.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Viral
  •  go-up   go-down


63. Zeng X, Wu SF, Zhou WX, Li DJ, Gao J, Liang ZY, Liu TH: [EGFR and HER2 gene expression status and their correlation in non-small cell lung cancer]. Zhonghua Bing Li Xue Za Zhi; 2006 Jul;35(7):398-402
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [EGFR and HER2 gene expression status and their correlation in non-small cell lung cancer].
  • OBJECTIVE: To explore epidermal growth factor receptor (EGFR) and HER2 gene status, to assess the correlation between EGFR and HER2 gene status, and to investigate the role of copy number increase and amplification of EGFR gene and HER2 gene in the tumorigenesis and disease progression of non-small-cell lung cancer.
  • METHODS: Using Path Vysion kit and LSI EGFR SpectrumOrange/CEP7 Spectrum Green probes, EGFR gene and HER2 gene status were evaluated by fluorescence insitu hybridization (FISH) using formalin-fixed, paraffin-embedded samples from 31 patients with non-small-cell lung cancer, including 20 adenocarcinomas, 2 squamous cell carcinomas, 2 large cell carcinoma, 4 bronchoalveolar carcinomas and 3 adenosquamous carcinomas.
  • RESULTS: Six of thirty-one carcinomas showed EGFR gene amplification.
  • Overall, 15 out of 31 carcinomas demonstrated either EGFR gene copy number increase or gene amplification (15/31).
  • EGFR gene numerical changes significantly correlated with HER2 gene abnormality (chi(2)(Adj) = 7.3045, P = 0.0069).
  • CONCLUSIONS: EGFR or HER2 copy number increase is much more frequent than gene amplification in no-small-cell lung cancer.
  • The interactions between EGFR and HER2 may play a rule in the progression of non-small-cell lung cancer.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / pathology. Genes, erbB-1 / genetics. Genes, erbB-2 / genetics. Lung Neoplasms / pathology


64. Bonde P, Sui G, Dhara S, Wang J, Broor A, Kim IF, Wiley JE, Marti G, Duncan M, Jaffee E, Montgomery E, Maitra A, Harmon JW: Cytogenetic characterization and gene expression profiling in the rat reflux-induced esophageal tumor model. J Thorac Cardiovasc Surg; 2007 Mar;133(3):763-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: The reasons for the increasing incidence of esophageal adenocarcinoma are not clear.
  • A causal relation between gastroesophageal reflux disease and esophageal adenocarcinoma has been suggested.
  • Support for this comes from the development of esophageal adenocarcinoma in the rat reflux model.
  • Three cell lines were established from 2 of the reflux-associated tumors.
  • Furthermore, we performed a cytogenetic analysis and determined the array-based gene expression profiles of these 3 rodent carcinoma lines compared with normal esophageal mucosa.
  • RESULTS: At 9 months, 12 of 12 rodents had histologic features of metaplastic columnar epithelium in the esophagus, with 7 having invasive carcinomas with glandular differentiation (either adenocarcinomas or adenosquamous carcinomas).
  • The 3 cell lines established from 2 reflux-associated tumors were capable of sustained in vitro propagation and grew successfully as xenografts in both subcutaneous and orthotopic locations, confirming the tumorigenic nature of these lines.
  • Despite their establishment from primary tumors with glandular features, the histology of the xenografts was that of well-differentiated squamous carcinomas.
  • Cell lines have been established from these tumors that are capable of in vitro and in vivo passaging.
  • The rodent reflux model should be a valuable model for studying therapy and chemoprevention efforts for Barrett esophagus, whereas the established cell lines provide a useful resource for drug discovery and other high-throughput studies.
  • [MeSH-major] Adenocarcinoma / genetics. Cell Transformation, Neoplastic / pathology. Esophageal Neoplasms / genetics. Gastroesophageal Reflux / genetics
  • [MeSH-minor] Animals. Cell Line, Tumor. Cytogenetic Analysis. DNA, Complementary / analysis. Disease Models, Animal. Gene Expression Profiling. Gene Expression Regulation, Neoplastic. In Vitro Techniques. Male. Mice. Mice, Nude. Neoplasms, Experimental. Rats. Rats, Sprague-Dawley. Reverse Transcriptase Polymerase Chain Reaction. Sensitivity and Specificity. Transplantation, Heterologous

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - GERD.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17320581.001).
  • [ISSN] 1097-685X
  • [Journal-full-title] The Journal of thoracic and cardiovascular surgery
  • [ISO-abbreviation] J. Thorac. Cardiovasc. Surg.
  • [Language] eng
  • [Grant] United States / FIC NIH HHS / TW / D43 TW06176
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Complementary
  •  go-up   go-down


65. Fadare O, Reddy H, Wang J, Hileeto D, Schwartz PE, Zheng W: E-Cadherin and beta-Catenin expression in early stage cervical carcinoma: a tissue microarray study of 147 cases. World J Surg Oncol; 2005;3:38
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] E-Cadherin and beta-Catenin expression in early stage cervical carcinoma: a tissue microarray study of 147 cases.
  • Alterations in the cell-cell adhesion complex, E-Cadherin/beta-Catenin, have been implicated in the oncogenesis of carcinomas arising from various anatomic sites and have been correlated with adverse clinico-pathologic parameters.
  • PATIENTS AND METHODS: A tissue microarray of 147 cases of FIGO stage 1A and 1B cervical carcinomas [96 squamous cell carcinomas (SCC), 35 adenocarcinomas (AC), 12 adenosquamous carcinomas (ASQ), 4 miscellaneous types] was constructed from our archived surgical pathology files and stained with monoclonal antibodies to E-Cadherin and beta-Catenin.
  • There was no correlation between the status of both markers for all three histological subtypes (overall spearman correlation co-efficient r = 0.12, p = 0.14) CONCLUSION: Impairment of E-Cadherin and beta-Catenin expression is very frequent in early stage cervical cancers, and alterations in the E-Cadherin/beta-Catenin cell adhesion complex are therefore likely involved in the pathogenesis of cervical carcinomas even at their earliest stages.
  • None of the three major histological subtypes of cervical carcinoma (SCC, ADCA, ADSQ) is significantly more likely than the others to show impairment in E-Cadherin and beta-Catenin expression.

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1989 Nov 15;64(10):2184-90 [2804908.001]
  • [Cites] Cancer Res. 1994 Jul 15;54(14):3929-33 [7518346.001]
  • [Cites] Mod Pathol. 1994 Oct;7(8):835-41 [7530850.001]
  • [Cites] Cancer. 1994 Jan 1;73(1):140-7 [8275416.001]
  • [Cites] J Cell Biol. 1993 Feb;120(3):757-66 [8425900.001]
  • [Cites] EMBO J. 1995 Dec 15;14(24):6107-15 [8557030.001]
  • [Cites] Cancer Res. 1996 Sep 15;56(18):4154-8 [8797585.001]
  • [Cites] J Cell Biochem. 1996 Jun 15;61(4):514-23 [8806074.001]
  • [Cites] Gynecol Oncol. 1997 Mar;64(3):481-6 [9062155.001]
  • [Cites] Curr Biol. 1997 May 1;7(5):308-15 [9133345.001]
  • [Cites] J Pathol. 1997 Jul;182(3):325-30 [9349236.001]
  • [Cites] J Pathol. 1997 Jul;182(3):331-8 [9349237.001]
  • [Cites] Int J Cancer. 1997 Oct 21;74(5):523-8 [9355975.001]
  • [Cites] Br J Cancer. 1997;76(9):1131-3 [9365159.001]
  • [Cites] J Pathol. 1997 Dec;183(4):404-11 [9496256.001]
  • [Cites] Nature. 1998 Mar 12;392(6672):190-3 [9515965.001]
  • [Cites] Nat Med. 1998 Jul;4(7):844-7 [9662379.001]
  • [Cites] Am J Pathol. 1998 Nov;153(5):1521-30 [9811344.001]
  • [Cites] Hum Pathol. 1999 Apr;30(4):458-66 [10208469.001]
  • [Cites] Gynecol Oncol. 1999 May;73(2):177-83 [10329031.001]
  • [Cites] Br J Cancer. 1999 May;80(3-4):322-30 [10408833.001]
  • [Cites] Am J Pathol. 1999 Aug;155(2):505-15 [10433943.001]
  • [Cites] Oncogene. 1999 Dec 20;18(55):7860-72 [10630639.001]
  • [Cites] Science. 2000 Mar 3;287(5458):1606-9 [10733430.001]
  • [Cites] Lab Invest. 2000 Dec;80(12):1943-9 [11140706.001]
  • [Cites] Verh Dtsch Ges Pathol. 2000;84:28-32 [11217445.001]
  • [Cites] Zhonghua Zhong Liu Za Zhi. 2000 Nov;22(6):496-8 [11235574.001]
  • [Cites] Cancer J. 2001 Jan-Feb;7(1):24-31 [11269645.001]
  • [Cites] Exp Mol Pathol. 2001 Jun;70(3):255-64 [11418004.001]
  • [Cites] Gynecol Oncol. 2001 Sep;82(3):450-5 [11520139.001]
  • [Cites] Int J Mol Med. 2001 Oct;8(4):353-8 [11562771.001]
  • [Cites] J Clin Invest. 2002 Apr;109(8):987-91 [11956233.001]
  • [Cites] Genes Chromosomes Cancer. 2002 Jul;34(3):255-68 [12007186.001]
  • [Cites] Am J Surg Pathol. 2002 Jun;26(6):758-66 [12023580.001]
  • [Cites] Mod Pathol. 2002 Dec;15(12):1374-80 [12481020.001]
  • [Cites] Cancer. 2003 Jun 15;97(12 Suppl):3133-275 [12784323.001]
  • [Cites] Zhonghua Zhong Liu Za Zhi. 2003 Jul;25(4):372-5 [12921570.001]
  • [Cites] Cancer J. 2003 Sep-Oct;9(5):395-403 [14690315.001]
  • [Cites] Histopathology. 2004 Feb;44(2):97-108 [14764053.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2003 Jul;8(3):347-58 [14973378.001]
  • [Cites] CA Cancer J Clin. 2004 Jan-Feb;54(1):8-29 [14974761.001]
  • [Cites] Science. 2004 Mar 5;303(5663):1483-7 [15001769.001]
  • [Cites] Bioessays. 2004 May;26(5):497-511 [15112230.001]
  • [Cites] Lab Invest. 2004 Aug;84(8):1071-8 [15195116.001]
  • [Cites] Gynecol Oncol. 2004 Aug;94(2):521-7 [15297198.001]
  • [Cites] Chin Med J (Engl). 2004 Aug;117(8):1232-9 [15361301.001]
  • [Cites] Int J Gynecol Pathol. 2004 Oct;23(4):337-46 [15381903.001]
  • [Cites] Pathobiology. 2004;71(6):329-36 [15627844.001]
  • [Cites] Am J Obstet Gynecol. 1992 Apr;166(4):1254-9 [1566781.001]
  • [Cites] Acta Cytol. 1990 May-Jun;34(3):366-72 [2111625.001]
  • [Cites] JAMA. 1989 Feb 3;261(5):737-43 [2642983.001]
  • (PMID = 15969753.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1183253
  •  go-up   go-down


66. Sorbe B, Bohr L, Karlsson L, Bermark B: Combined external and intracavitary irradiation in treatment of advanced cervical carcinomas: predictive factors for local tumor control and early recurrences. Int J Oncol; 2010 Feb;36(2):371-8
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined external and intracavitary irradiation in treatment of advanced cervical carcinomas: predictive factors for local tumor control and early recurrences.
  • In a series of 131 primary cervical carcinomas in FIGO stages I-IV suitable for combined external pelvic and intraluminal cervical-vaginal brachytherapy predictive and prognostic factors were analyzed with regard to locoregional tumor control, recurrences and survival data.
  • One hundred and seven tumors were squamous cell carcinomas (82%) and 24 adenocarcinomas or adenosquamous carcinomas.
  • Squamous cell carcinomas had complete remission in 96% and adenocarcinomas in 81% (Pearson Chi-square; P=0.00002).
  • A lower FIGO stage, chemoradiotherapy, squamous cell histology, diploid DNA-profile, a higher brachytherapy dose, more brachytherapy fractions and a higher total combined irradiation dose were favorable factors with regard to the risk of tumor recurrences.
  • Chemoradiotherapy therapy versus radiotherapy alone and squamous cell carcinomas versus adenocarcinomas were associated with improved survival rates.
  • [MeSH-major] Brachytherapy / methods. Carcinoma / radiotherapy. Neoplasm Recurrence, Local / radiotherapy. Radiotherapy / methods. Uterine Cervical Neoplasms / radiotherapy

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20043071.001).
  • [ISSN] 1791-2423
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


67. Wang J, Wang FW, Lagrange CA, Hemstreet GP: Clinical features and outcomes of 25 patients with primary adenosquamous cell carcinoma of the prostate. Rare Tumors; 2010;2(3):e47

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical features and outcomes of 25 patients with primary adenosquamous cell carcinoma of the prostate.
  • The aim of the present study was to examine the epidemiology, natural history, treatment and long-term survival of patients with adenosquamous cell carcinoma of the prostate.
  • A total of 25 patients with adenosquamous cell carcinoma of the prostate were identified during the study period.
  • Twenty percent of study subjects presented with metastatic disease.
  • Adenosquamous cell carcinoma is a rare aggressive subtype of prostate cancer with poor cancer specific survival.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21139962.001).
  • [ISSN] 2036-3613
  • [Journal-full-title] Rare tumors
  • [ISO-abbreviation] Rare Tumors
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Other-IDs] NLM/ PMC2994527
  • [Keywords] NOTNLM ; ASCC / SEER / adenosquamous cell carcinoma / and end results / cancer specific survival / epidemiology / prostate / surveillance
  •  go-up   go-down


68. Kobashi Y, Mouri K, Fukuda M, Yoshida K, Miyashita N, Niki Y, Nakata M, Mikio O: [A case of pulmonary adenosquamous cell carcinoma with thin-wall cavities]. Nihon Kokyuki Gakkai Zasshi; 2005 Jan;43(1):59-62
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of pulmonary adenosquamous cell carcinoma with thin-wall cavities].
  • A histological diagnosis of pulmonary adenocarcinoma was obtained by bronchoscopic examination, and he was transferred to the Department of Thoracic Surgery where a right upper lobectomy was performed.
  • Most of the surrounding cavity consisted of the components of a well differentiated squamous cell carcinoma with keratinization and slightly different components of a poorly differentiated adenocarcinoma with mucous production.
  • The final diagnosis was pulmonary adenosquamous cell carcinoma and the postoperative histological classification was T2N2M0 (Stage 3A) because of metastasis to the lymph nodes (#4 and #11).
  • Although squamous cell carcinoma has been reported to be the histological type, tending to form thin-wall cavities among patients with lung cancer reported to be squamous cell carcinoma, recently an increasing number of such cavities have been reported among patients with pulmonary adenocarcinoma.
  • Herein, we have reported a rare case of histological diagnosis of pulmonary adenosquamous cell carcinoma with cavity formation.
  • [MeSH-major] Carcinoma, Adenosquamous / pathology. Lung / pathology. Lung Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15704455.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


69. Kim YS, Heo WS, Chae KH, Gang YS, Jung JH, Kim SH, Seong JK, Lee BS, Jeong HY, Song KS, Shin KS, Cho JS, Noh SM: [Clinicopathological features and differences of p53 and Ki-67 expression in adenosquamous and squamous cell carcinomas of the stomach]. Korean J Gastroenterol; 2006 Jun;47(6):425-31
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinicopathological features and differences of p53 and Ki-67 expression in adenosquamous and squamous cell carcinomas of the stomach].
  • BACKGROUND/AIMS: This study reviews the clinicopathological features, prognosis, and differences in the expression of p53 and Ki-67 immunochemical staining in squamous cell and adenosquamous carcinoma of the stomach.
  • METHODS: From January 1995 to June 2005, 2,282 cases of gastric carcinoma were resected surgically in our hospital and 191 additional cases were resected by endoscopic mucosal resection.
  • RESULTS: The study consists of eight cases (0.032%) of primary squamous cell carcinoma (one case) and adenosquamous carcinoma (seven cases) without early gastric cancer.
  • The clinical presentation and physical findings did not differ from those of adenocarcinoma.
  • At the initial diagnosis, six (75%) were stage IV based on TNM tumor staging.
  • CONCLUSIONS: Adenosquamous and squamous cell carcinoma of the stomach are very rare.
  • They tend to be at advanced stages on initial diagnosis, and progress rapidly.
  • [MeSH-major] Carcinoma, Adenosquamous / pathology. Carcinoma, Squamous Cell / pathology. Ki-67 Antigen / analysis. Stomach Neoplasms / pathology. Tumor Suppressor Protein p53 / analysis

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16809949.001).
  • [ISSN] 1598-9992
  • [Journal-full-title] The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
  • [ISO-abbreviation] Korean J Gastroenterol
  • [Language] kor
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


70. Terada T: Adenosquamous carcinoma of the ovary arising from endometriosis: two case reports. Cases J; 2009;2:6661

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenosquamous carcinoma of the ovary arising from endometriosis: two case reports.
  • The author reports two cases of adenosquamous carcinoma arising from endometriosis of ovaries.
  • Both patients underwent hysterectomy and bilateral salpingo-oophorectomy for ovarian carcinomas.
  • Histologically, the cystic areas consisted of endometrial glandular epithelium.
  • Both mural tumors were composed of grade I endometroid adenocarcinoma and squamous cell carcinoma.
  • A differentiation of endometrioid adenocarcinoma from the endometriosis were present in a few areas.
  • Likewise, a differentiation of squamous cell carcinoma from the endometriosis were recognized in several areas.
  • The pathologic diagnosis was adenosquamous carcinoma arising from endometriosis of the ovary in both cases, rather than endometrioid adenocarcinoma with malignant squamous differentiation.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1978 Jul;42(1):326-9 [208753.001]
  • [Cites] Gynecol Obstet Invest. 2000;50 Suppl 1:11-7 [11093056.001]
  • [Cites] Clin Obstet Gynecol. 1966 Jun;9(2):384-411 [5330412.001]
  • [Cites] Gynecol Oncol. 1988 May;30(1):143-8 [3366390.001]
  • (PMID = 20184682.001).
  • [ISSN] 1757-1626
  • [Journal-full-title] Cases journal
  • [ISO-abbreviation] Cases J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2827079
  •  go-up   go-down


71. Mingoli A, Brachini G, Petroni R, Antoniozzi A, Cavaliere F, Simonelli L, Chirletti P, Modini C: Squamous and adenosquamous cell carcinomas of the gallbladder. J Exp Clin Cancer Res; 2005 Mar;24(1):143-50
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Squamous and adenosquamous cell carcinomas of the gallbladder.
  • Squamous and adenosquamous cell carcinomas (ASC and SCC) are rare subtypes of gallbladder cancer, traditionally considered more aggressive and with a poorer prognosis than adenocarcinoma.
  • We report about two patients affected by an advanced squamous cell carcinoma of the gallbladder.
  • In conclusion, an aggressive and radical surgical treatment of advanced squamous and adenosquamous cell gallbladder carcinomas seems to be indicated for their low proclivity to distant spreading.
  • [MeSH-major] Carcinoma, Adenosquamous / pathology. Carcinoma, Squamous Cell / pathology. Gallbladder Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15943044.001).
  • [ISSN] 0392-9078
  • [Journal-full-title] Journal of experimental & clinical cancer research : CR
  • [ISO-abbreviation] J. Exp. Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 50
  •  go-up   go-down


72. Dong Y, Wang J, Ma H, Zhou H, Lu G, Zhou X: Primary adenosquamous carcinoma of the colon: report of five cases. Surg Today; 2009;39(7):619-23
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary adenosquamous carcinoma of the colon: report of five cases.
  • Primary adenosquamous cell carcinomas (Ad-SCCs) of the colon and rectum are rare malignancies with a poor prognosis, in comparison to adenocarcinoma alone.
  • Different roles of human papilloma virus (HPV) in its pathogenesis have been reported and the role of P16 in Ad-SCCs has not been explored.
  • This report presents five cases of Ad-SCC of the colon to explore the clinicopathological features and the roles of P16, HPV 6/11, and 16/18.
  • There was no confirmed evidence to support the relationship between the infection of HPV 6/11, 16/18, and pathogenesis of Ad-SCC of the colon.
  • P16 overexpression was not related to HPV carcinogenesis and there might be another mechanism of P16 upregulation in Ad-SCC of the colon.
  • [MeSH-major] Alphapapillomavirus / isolation & purification. Carcinoma, Adenosquamous / pathology. Carcinoma, Adenosquamous / virology. Colonic Neoplasms / pathology. Colonic Neoplasms / virology. Papillomavirus Infections / virology

  • MedlinePlus Health Information. consumer health - HPV.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19562453.001).
  • [ISSN] 1436-2813
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / P16 protein, human
  •  go-up   go-down


73. Uramoto H, Yamada S, Hanagiri T: Immunohistochemical staining with deltaNp63 is useful for distinguishing the squamous cell component of adenosquamous cell carcinoma of the lung. Anticancer Res; 2010 Nov;30(11):4717-20
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical staining with deltaNp63 is useful for distinguishing the squamous cell component of adenosquamous cell carcinoma of the lung.
  • The aim of this study was to detect the deltaNp63 expression in the squamous carcinoma component of adenosquamous carcinoma and evaluate its usefulness as a specific squamous carcinoma marker.
  • PATIENTS AND METHODS: Immunohistochemistry was used to analyze the protein expression of deltaNp63 and high molecular weight cytokeratin in paraffin-embedded tumor samples from 17 patients with well-characterized adenosquamous carcinoma.
  • It was easy to discriminate the squamous carcinoma and adenocarcinoma components in all tumors.
  • CONCLUSION: These findings indicated that the deltaNp63 status was useful for distinguishing squamous carcinoma from adenocarcinoma in formalin-postfixed adenosquamous carcinoma specimens.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Carcinoma, Adenosquamous / metabolism. Carcinoma, Non-Small-Cell Lung / metabolism. Carcinoma, Squamous Cell / metabolism. Lung Neoplasms / metabolism. Trans-Activators / metabolism. Tumor Suppressor Proteins / metabolism

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21115930.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / TP63 protein, human; 0 / Trans-Activators; 0 / Transcription Factors; 0 / Tumor Suppressor Proteins; 68238-35-7 / Keratins
  •  go-up   go-down


74. Uramoto H, Yamada S, Hanagiri T: Clinicopathological characteristics of resected adenosquamous cell carcinoma of the lung: risk of coexistent double cancer. J Cardiothorac Surg; 2010;5:92
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathological characteristics of resected adenosquamous cell carcinoma of the lung: risk of coexistent double cancer.
  • BACKGROUND: adenosquamous carcinoma (ADSQ) of non-small cell lung cancer (NSCLC) is a rare disease and the biological behavior and clinicopathological characteristics have not yet been thoroughly described.
  • ADSQ was found less frequently in males than squamous cell carcinoma (SQ).
  • ADSQ was found more frequently in older patients, with advanced stage, advanced T status, and lymph node metastases than adenocarcinoma (AD).
  • The proportion with coexistent double cancer of AD, SQ, and ADSQ were 21.1, 17.6, and 45.5%, respectively.
  • CONCLUSIONS: In this study, cases with ADSQ showed no significantly prognostic difference in comparison to AD and SQ.
  • [MeSH-major] Carcinoma, Adenosquamous / pathology. Carcinoma, Non-Small-Cell Lung / pathology. Lung Neoplasms / pathology. Neoplasms, Multiple Primary / diagnosis

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Chest. 1996 Apr;109(4):989-94 [8635382.001]
  • [Cites] Cancer Invest. 1993;11(6):641-51 [8221196.001]
  • [Cites] Oncol Rep. 1998 Jul-Aug;5(4):861-5 [9625833.001]
  • [Cites] Scand Cardiovasc J. 1999;33(1):29-32 [10093856.001]
  • [Cites] Respir Med. 2006 Dec;100(12):2073-84 [17056245.001]
  • [Cites] Ann Thorac Surg. 2007 Aug;84(2):702-7 [17643676.001]
  • [Cites] Med Oncol. 2009;26(1):27-31 [18483884.001]
  • [Cites] Am J Pathol. 2000 Apr;156(4):1289-98 [10751354.001]
  • [Cites] Jpn J Cancer Res. 1999 Nov;90(11):1244-7 [10622536.001]
  • [Cites] Chest. 2000 Feb;117(2):374-9 [10669677.001]
  • [Cites] Ann Thorac Surg. 2003 Jun;75(6):1740-4 [12822609.001]
  • [Cites] Natl Cancer Inst Monogr. 1985 Dec;68:219-42 [4088299.001]
  • [Cites] Ann Thorac Surg. 1987 Nov;44(5):462-6 [3675050.001]
  • [Cites] Am Rev Respir Dis. 1990 Jul;142(1):19-23 [2368969.001]
  • [Cites] Cancer. 1991 Feb 1;67(3):649-54 [1985759.001]
  • [Cites] Am J Clin Pathol. 1992 May;97(5):678-85 [1575214.001]
  • [Cites] Ann Thorac Surg. 1993 Mar;55(3):593-6 [8452418.001]
  • [Cites] Chest. 1997 Jun;111(6):1710-7 [9187198.001]
  • (PMID = 21034441.001).
  • [ISSN] 1749-8090
  • [Journal-full-title] Journal of cardiothoracic surgery
  • [ISO-abbreviation] J Cardiothorac Surg
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cyclic AMP-Dependent Protein Kinase RIalpha Subunit
  • [Other-IDs] NLM/ PMC2987925
  •  go-up   go-down


75. Ogura K, Ishi K, Matsumoto T, Kina K, Nojima M, Suda K: Human papillomavirus localization in cervical adenocarcinoma and adenosquamous carcinoma using in situ polymerase chain reaction: review of the literature of human papillomavirus detection in these carcinomas. Pathol Int; 2006 Jun;56(6):301-8
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human papillomavirus localization in cervical adenocarcinoma and adenosquamous carcinoma using in situ polymerase chain reaction: review of the literature of human papillomavirus detection in these carcinomas.
  • Many studies have suggested that human papillomavirus (HPV) infection plays an important role in the carcinogenesis of the cervical adenocarcinoma.
  • However, the prevalence of HPV infection in cervical adenocarcinoma and adenosquamous carcinoma varies among the studies.
  • Cervical adenocarcinoma (24 cases) and adenosquamous carcinoma (16 cases), including the underlying non-neoplastic epithelium were examined for HPV-DNA using in situ polymerase chain reaction (PCR), which enabled visualization of the localization on a glass slide.
  • In adenocarcinoma, HPV-DNA was found in 13 cases (54%) and in eight cases in underlying non-neoplastic epithelium, resulting in a total of 21 positive cases (88%).
  • In adenosquamous carcinoma, HPV-DNA was detected in 12 cases (75%) and and the HPV-DNA localization of each component was pure adenocarcinoma, 28.6%; mixed, 54.5%; and pure squamous cell carcinoma, 83.3%.
  • In the underlying non-neoplastic epithelium, HPV-DNA was found more frequently in the squamous epithelium (73.3%) than the cervical glands (6.3%).
  • In conclusion, HPV-DNA was detected in 54% of adenocarcinoma, and the rate was elevated by HPV localization in the underlying non-neoplastic epithelium.
  • HPV infection in the underlying squamous epithelium might be related to the carcinogenesis, even in cervical adenocarcinoma.
  • HPV-DNA localization was different in each component of adenosquamous carcinoma.
  • [MeSH-major] Adenocarcinoma / virology. Carcinoma, Adenosquamous / virology. Papillomaviridae / isolation & purification. Papillomavirus Infections / pathology. Uterine Cervical Neoplasms / virology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16704493.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / DNA Probes, HPV; 0 / DNA, Viral
  •  go-up   go-down


76. Yasuda S, Kojima A, Maeno Y, Oki N, Miyahara Y, Sudo T, Takekida S, Yamaguchi S, Nishimura R: Poor prognosis of patients with stage Ib1 adenosquamous cell carcinoma of the uterine cervix with pelvic lymphnode metastasis. Kobe J Med Sci; 2006;52(1-2):9-15
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Poor prognosis of patients with stage Ib1 adenosquamous cell carcinoma of the uterine cervix with pelvic lymphnode metastasis.
  • From January 1990 to December 2004, the prognosis of 28 patients with stage Ib1 adenosquamous cell carcinoma (ASC) were assessed in comparison with those of matched counterparts of pure adenocarcinoma (ADC) and squamous cell carcinoma (SCC).
  • There was also no significant difference in the incidence of lymphatic or vascular space involvement (LVSI) and depth of stromal invasion between three cell types.
  • Since the tumor sizes of all ASC cases examined in this study were less than 4 cm, the prognoses were compared among stage Ib1 disease according to the classification system of the International Federation of Gynecology and Obstetrics (FIGO).
  • While all 9 patients in the low-risk group are alive without disease, 7 of the 19 patients in the high-risk group developed recurrence.
  • [MeSH-major] Carcinoma, Adenosquamous / pathology. Lymphatic Metastasis / pathology. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / mortality. Adenocarcinoma / pathology. Adenocarcinoma / secondary. Adenocarcinoma / surgery. Chemotherapy, Adjuvant. Female. Humans. Hysterectomy. Lymph Node Excision. Middle Aged. Neoplasm Staging. Pelvis. Prognosis. Retrospective Studies. Survival Rate


77. Aréchaga-Ocampo E, Pereira-Suárez AL, del Moral-Hernández O, Cedillo-Barrón L, Rodríguez-Sastre MA, Castillo-Alvarez A, López-Bayghen E, Villegas-Sepúlveda N: HPV+ cervical carcinomas and cell lines display altered expression of caspases. Gynecol Oncol; 2008 Jan;108(1):10-8
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HPV+ cervical carcinomas and cell lines display altered expression of caspases.
  • We analyzed here, the basal expression of precursors of apoptotic Caspases in normal cervical epithelium, HPV+ cervical tumor samples and HPV+ tumor-derived cell lines.
  • METHODS: Expression of initiator and effector Caspases was analyzed by immunochemistry in normal cervical epithelium and three types of cervical tumors (squamous cell carcinoma, adenocarcinoma and adenosquamous cell carcinoma) whereas expression of Caspases in HeLa, SiHa and CaSki cells was by immunofluorescence, Western blot and RT-PCR.
  • RESULTS: Expression of Caspases 3 and 9 was undetectable in adenocarcinoma and adenosquamous cell carcinoma, respectively.
  • Whereas in squamous cell carcinoma, the expression of Caspases was similar those observed in normal samples.
  • We did not observe an effect of the E6/E7 oncogenes on the expression of Caspases in C33-A cell.
  • CONCLUSION: Our results showed a differential expression of several Caspases in carcinoma samples and cell lines, suggesting multiple alterations of the Caspase pathways in cervical cancer.
  • [MeSH-minor] Adenocarcinoma / enzymology. Adenocarcinoma / pathology. Adenocarcinoma / virology. Blotting, Western. Carcinoma, Adenosquamous / enzymology. Carcinoma, Adenosquamous / pathology. Carcinoma, Adenosquamous / virology. Carcinoma, Squamous Cell / enzymology. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / virology. Cell Line, Tumor. Female. Fluorescent Antibody Technique. HeLa Cells. Human papillomavirus 16. Human papillomavirus 18. Humans. Immunohistochemistry. Isoenzymes / biosynthesis. Paraffin Embedding. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17936882.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Isoenzymes; EC 3.4.22.- / Caspases
  •  go-up   go-down


78. Alwaheeb S, Chetty R: Adenosquamous carcinoma of the pancreas with an acantholytic pattern together with osteoclast-like and pleomorphic giant cells. J Clin Pathol; 2005 Sep;58(9):987-90
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenosquamous carcinoma of the pancreas with an acantholytic pattern together with osteoclast-like and pleomorphic giant cells.
  • Histological evaluation of the pancreatic tumour showed an adenosquamous carcinoma (predominantly composed of squamous carcinoma), which was extensively infiltrative with perineural invasion and involvement of peripancreatic lymph nodes.
  • Areas of pancreatic intraepithelial neoplasia grade III and merging of the squamous and adenocarcinoma components were evident.
  • Unusual histological features that characterised this case included a pronounced acantholytic pattern within the squamous carcinoma component, and the presence of both osteoclastic and pleomorphic giant cells.
  • Giant cells have not been documented previously in association with an adenosquamous carcinoma.
  • Although an acantholytic pattern has been noted in squamous carcinomas in other sites, this is the first report of such a pattern in an adenosquamous carcinoma of the pancreas.
  • [MeSH-major] Carcinoma, Adenosquamous / pathology. Giant Cells / pathology. Osteoclasts / pathology. Pancreatic Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Pathol. 2000 Oct;31(10):1223-9 [11070115.001]
  • [Cites] Mod Pathol. 2001 May;14(5):443-51 [11353055.001]
  • [Cites] JOP. 2004 Jul;5(4):220-4 [15254351.001]
  • [Cites] Cancer. 1972 May;29(5):1133-40 [5021607.001]
  • [Cites] J Surg Oncol. 1973;5(4):335-58 [4355621.001]
  • [Cites] J Surg Oncol. 1980;14(3):261-5 [7392648.001]
  • [Cites] Gastroenterology. 1982 Dec;83(6):1297-9 [7129033.001]
  • [Cites] Acta Cytol. 1984 Nov-Dec;28(6):733-6 [6594886.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1988;412(3):247-53 [3124345.001]
  • [Cites] Gan No Rinsho. 1990 May;36(6):728-32 [2348561.001]
  • [Cites] Hum Pathol. 1991 Jun;22(6):618-22 [1864595.001]
  • [Cites] Hum Pathol. 1992 Jun;23(6):703-6 [1592394.001]
  • [Cites] Pancreas. 1992;7(5):611-5 [1513808.001]
  • [Cites] Pathology. 1993 Oct;25(4):420-2 [8165013.001]
  • [Cites] Int J Pancreatol. 1995 Oct;18(2):169-75 [8530833.001]
  • [Cites] Cancer. 1998 Apr 1;82(7):1279-87 [9529019.001]
  • [Cites] Pathol Res Pract. 1998;194(8):587-94; discussion 595 [9779494.001]
  • [Cites] Arch Surg. 1999 Jun;134(6):599-603 [10367867.001]
  • [Cites] AMA Arch Pathol. 1954 Aug;58(2):101-11 [13170907.001]
  • [Cites] Int J Pancreatol. 1999 Oct;26(2):85-91 [10597404.001]
  • [Cites] Pathol Int. 2000 Jul;50(7):562-7 [10886741.001]
  • (PMID = 16126885.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1770836
  •  go-up   go-down


79. Akcali Z, Ozyilkan O, Sakalli H, Bal N, Noyan T: Gallbladder adenosquamous cell carcinoma: report of two cases. Acta Gastroenterol Belg; 2005 Oct-Dec;68(4):440-2
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gallbladder adenosquamous cell carcinoma: report of two cases.
  • Adenocarcinoma is the usual histological presentation of the very rare gallbladder carcinoma.
  • Adenosquamous cell carcinoma accounts for less than 3.5% of gallbladder carcinomas, and is characterised by invasive growth, a reduced tendency for lymph node metastasis, an increased tendency for hepatic infiltration or liver metastasis, and a poorer prognosis than adenocarcinoma.
  • Adenosquamous carcinoma of the gallbladder was diagnosed on the post-operative pathological specimen.
  • Cytology specimens obtained with an endoscopic retrograde cholangiopancreatography (ERCP) procedure revealed a malignant epithelial tumour.
  • [MeSH-major] Carcinoma, Adenosquamous / pathology. Carcinoma, Adenosquamous / surgery. Gallbladder Neoplasms / pathology. Gallbladder Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16432998.001).
  • [ISSN] 1784-3227
  • [Journal-full-title] Acta gastro-enterologica Belgica
  • [ISO-abbreviation] Acta Gastroenterol. Belg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Belgium
  • [Chemical-registry-number] 1548R74NSZ / Tegafur; U3P01618RT / Fluorouracil
  •  go-up   go-down


80. Faria GR, Eloy C, Preto JR, Costa EL, Almeida T, Barbosa J, Paiva ME, Sousa-Rodrigues J, Pimenta A: Primary gastric adenosquamous carcinoma in a Caucasian woman: a case report. J Med Case Rep; 2010;4:351

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary gastric adenosquamous carcinoma in a Caucasian woman: a case report.
  • Primary gastric adenosquamous carcinoma is a rare malignancy, mostly associated with Asian populations.
  • It constitutes less than one percent of all gastric carcinomas and its clinical presentation is the same as adenocarcinoma.
  • It occurs more frequently in the proximal stomach, usually presents with muscular layer invasion and tends to be found in advanced stages at diagnosis, with a worse prognosis than adenocarcinoma.
  • CASE PRESENTATION: We report the case of an 84-year-old Caucasian woman with an adenosquamous carcinoma extending to her serosa with lymphatic and venous invasion (T3N1M1).
  • Nodal and hepatic metastasis presented with both cellular types, with dominance of the squamous component.
  • CONCLUSIONS: Adenosquamous gastric cancer is a rare diagnosis in western populations.
  • We present the case of a woman with a very aggressive adenosquamous carcinoma with a preponderance of squamous cell component in the metastasis.
  • Several origins have been proposed for this kind of carcinoma; either evolution from adenocarcinoma de-differentiation or stem cell origin might be possible.
  • The hypothesis that a particular histological type of gastric cancer may arise from stem cells might be a field of research in oncological disease of the stomach.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21034475.001).
  • [ISSN] 1752-1947
  • [Journal-full-title] Journal of medical case reports
  • [ISO-abbreviation] J Med Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2984469
  •  go-up   go-down


81. Yoshida T, Sano T, Oyama T, Kanuma T, Fukuda T: Prevalence, viral load, and physical status of HPV 16 and 18 in cervical adenosquamous carcinoma. Virchows Arch; 2009 Sep;455(3):253-9
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prevalence, viral load, and physical status of HPV 16 and 18 in cervical adenosquamous carcinoma.
  • Adenosquamous carcinoma of the uterine cervix is a rare mixture of malignant squamous and glandular epithelial elements and accounts for approximately 10% of cervical carcinomas.
  • The aims of the present study were to evaluate the prevalence, physical status, and viral load of HPV 16 and 18 in adenosquamous carcinoma.
  • Formalin-fixed paraffin-embedded tissue samples from 20 cases of histologically diagnosed adenosquamous carcinoma were examined.
  • The squamous and glandular components were separately microdissected and analyzed for their HPV DNA subtype, viral load, and physical status using real-time polymerase chain reaction (PCR).
  • The percentages of HPV 16- and 18-positive cases among all the HPV-positive cases were 36.8% (7/19) and 57.9% (11/19) in the squamous epithelial elements and 33.3% (6/18) and 61.1% (11/18) in the glandular elements, respectively.
  • The mean HPV 16 DNA copy numbers/cell was 7.22 in the squamous elements and 1.33 in the glandular elements (p=0.04) while the corresponding mean HPV 18 DNA copy numbers/cell was 1.50 and 0.89, respectively.
  • The prevalence of HPV 18 in adenosquamous carcinoma was high and many HPV 18-positive cases were the pure integrated form resulting in very low copy numbers/cell.
  • [MeSH-major] Carcinoma, Adenosquamous / virology. Human papillomavirus 16 / isolation & purification. Human papillomavirus 18 / isolation & purification. Uterine Cervical Neoplasms / virology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19727809.001).
  • [ISSN] 1432-2307
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / DNA, Viral
  •  go-up   go-down


82. Voong KR, Davison J, Pawlik TM, Uy MO, Hsu CC, Winter J, Hruban RH, Laheru D, Rudra S, Swartz MJ, Nathan H, Edil BH, Schulick R, Cameron JL, Wolfgang CL, Herman JM: Resected pancreatic adenosquamous carcinoma: clinicopathologic review and evaluation of adjuvant chemotherapy and radiation in 38 patients. Hum Pathol; 2010 Jan;41(1):113-22
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Resected pancreatic adenosquamous carcinoma: clinicopathologic review and evaluation of adjuvant chemotherapy and radiation in 38 patients.
  • Pancreatic adenosquamous carcinoma is a rare morphological variant of pancreatic adenocarcinoma with an especially poor prognosis.
  • The purpose of this study is to identify clinicopathologic features associated with prognosis, assess whether the percentage of squamous differentiation in pancreatic adenosquamous carcinoma is associated with an inferior prognosis, and examine the impact of adjuvant chemoradiation therapy on overall survival.
  • Forty-five (1.2%) of 3651 patients who underwent pancreatic resection at the Johns Hopkins Hospital, Baltimore, MD, between 1986 and 2007 were identified with adenocarcinoma of the pancreas with any squamous differentiation.
  • Seventy-six percent of carcinomas were node positive, 37% were margin-positive resections, and 68% had 30% or more squamous differentiation.
  • Median overall survival of the pancreatic adenosquamous carcinoma cohort was 10.9 months (range, 2.1-140.6 months; 95% confidence interval, 8.2-12.5 months).
  • Adjuvant chemoradiation therapy was associated with superior overall survival in patients with pancreatic adenosquamous carcinoma (P = .005).
  • The proportion of squamous differentiation was not associated with median overall survival (< 30% versus > or = 30%, P = .82).
  • Survival after pancreatic resection of pancreatic adenosquamous carcinoma is poor.
  • The proportion of squamous differentiation in resected pancreatic adenosquamous carcinoma specimens does not appear to impact overall survival.
  • [MeSH-major] Carcinoma, Adenosquamous / therapy. Pancreatic Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mod Pathol. 2009 May;22(5):651-9 [19270646.001]
  • [Cites] Acta Cytol. 1984 Nov-Dec;28(6):733-6 [6594886.001]
  • [Cites] Int J Pancreatol. 2001;29(1):53-8 [11558633.001]
  • [Cites] Ultrastruct Pathol. 1982 Jan-Mar;3(1):17-23 [7071952.001]
  • [Cites] Cancer. 2003 Dec 25;99(6):372-8 [14681946.001]
  • [Cites] J Gastroenterol. 2003;38(12):1171-5 [14714256.001]
  • [Cites] Cancer. 1972 May;29(5):1133-40 [5021607.001]
  • [Cites] Cancer Res. 1975 Aug;35(8):2234-48 [167949.001]
  • [Cites] Cancer. 1980 Sep 1;46(5):1192-6 [7214302.001]
  • [Cites] Mod Pathol. 2001 May;14(5):443-51 [11353055.001]
  • [Cites] Int J Pancreatol. 1999 Oct;26(2):85-91 [10597404.001]
  • [Cites] Abdom Imaging. 2000 Jul-Aug;25(4):420-3 [10926197.001]
  • [Cites] Diagn Cytopathol. 2001 Jul;25(1):38-42 [11466811.001]
  • [Cites] World J Gastroenterol. 2008 Nov 28;14(44):6765-70 [19058301.001]
  • [Cites] World J Surg Oncol. 2008;6:95 [18764955.001]
  • [Cites] J Am Coll Surg. 2008 Sep;207(3):368-70 [18722942.001]
  • [Cites] J Clin Oncol. 2008 Jul 20;26(21):3503-10 [18640931.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Int J Clin Oncol. 2008 Feb;13(1):74-7 [18307024.001]
  • [Cites] Drugs. 2007;67(16):2293-310 [17983252.001]
  • [Cites] JOP. 2007;8(3):330-4 [17495363.001]
  • [Cites] Digestion. 2005;72(2-3):104-8 [16172546.001]
  • [Cites] J Clin Pathol. 2005 Sep;58(9):987-90 [16126885.001]
  • [Cites] Arch Surg. 1999 Jun;134(6):599-603 [10367867.001]
  • [Cites] Acta Cytol. 1998 Nov-Dec;42(6):1451-4 [9850660.001]
  • [Cites] Am J Gastroenterol. 1998 Jul;93(7):1167-70 [9672355.001]
  • [Cites] Lifetime Data Anal. 1995;1(2):195-204 [9385101.001]
  • [Cites] Ann Surg. 1997 May;225(5):621-33; discussion 633-6 [9193189.001]
  • [Cites] J Surg Oncol. 1997 Feb;64(2):159-62 [9047255.001]
  • [Cites] J Surg Oncol. 1991 Jun;47(2):109-16 [2062081.001]
  • [Cites] Diagn Cytopathol. 1986 Jan-Mar;2(1):72-5 [3522134.001]
  • (PMID = 19801164.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA006973; United States / NCI NIH HHS / CA / T32 CA126607
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS433902; NLM/ PMC3556992
  •  go-up   go-down


83. Martinez JM, Stephens LC, Jones LA: Long-term effects of neonatal exposure to hydroxylated polychlorinated biphenyls in the BALB/cCrgl mouse. Environ Health Perspect; 2005 Aug;113(8):1022-6
Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The mice treated with OH-PCB-30 (200 microg/day) or 17beta-estradiol (5 microg/day) showed similar increased incidences of cervicovaginal (CV) tract carcinomas (43% and 47%, respectively).
  • In addition, when mice were treated with OH-PCBs as a mixture, a change in the type of CV tract tumor was observed, shifting from predominantly squamous cell carcinomas to adenosquamous cell carcinoma.

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Vaginal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Environ Health Perspect. 1999 Jan;107(1):45-51 [9872716.001]
  • [Cites] Chemosphere. 1998 Oct-Nov;37(9-12):1845-53 [9828313.001]
  • [Cites] Toxicol Lett. 1998 Dec 28;102-103:331-5 [10022274.001]
  • [Cites] Environ Health Perspect. 1999 Aug;107 Suppl 4:639-49 [10421775.001]
  • [Cites] Sci Total Environ. 1999 Aug 15;233(1-3):141-61 [10492903.001]
  • [Cites] J Natl Cancer Inst. 1963 Aug;31:425-55 [14046632.001]
  • [Cites] Toxicology. 2005 Mar 30;208(3):377-87 [15695023.001]
  • [Cites] Toxicol Sci. 2005 Mar;84(1):49-62 [15601674.001]
  • [Cites] J Natl Cancer Inst. 1976 Nov;57(5):1057-62 [187788.001]
  • [Cites] J Natl Cancer Inst. 1976 Nov;57(5):1185-9 [187796.001]
  • [Cites] Arch Pathol Lab Med. 1977 Jan;101(1):1-5 [576195.001]
  • [Cites] Environ Res. 1978 Jul;16(1-3):123-30 [98321.001]
  • [Cites] Arch Toxicol. 1978 Dec 28;41(3):179-86 [104695.001]
  • [Cites] Cancer Res. 1979 Jul;39(7 Pt 1):2560-7 [445458.001]
  • [Cites] J Pediatr. 1984 Aug;105(2):315-20 [6431068.001]
  • [Cites] Arch Environ Contam Toxicol. 1985 Jan;14(1):51-7 [3919656.001]
  • [Cites] Environ Health Perspect. 1985 May;60:35-9 [2992924.001]
  • [Cites] IARC Sci Publ. 1985;(65):107-17 [4086078.001]
  • [Cites] Environ Res. 1986 Oct;41(1):14-22 [3093216.001]
  • [Cites] Am J Pathol. 2000 Apr;156(4):1289-98 [10751354.001]
  • [Cites] Int J Cancer. 2001 Feb 15;91(4):568-74 [11251983.001]
  • [Cites] Environ Toxicol Chem. 2001 Feb;20(2):351-8 [11351435.001]
  • [Cites] Environ Health Perspect. 2001 Jul;109(7):739-47 [11485874.001]
  • [Cites] Arch Environ Contam Toxicol. 2002 Jan;42(1):105-17 [11706375.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Dec;11(12):1560-5 [12496044.001]
  • [Cites] Environ Sci Technol. 2003 Mar 1;37(5):832-9 [12666909.001]
  • [Cites] Environ Health Perspect. 2003 Apr;111(4):389-94 [12676588.001]
  • [Cites] Cancer. 2003 May 1;97(9):2196-202 [12712471.001]
  • [Cites] Environ Health Perspect. 2004 Aug;112(11):1208-12 [15289169.001]
  • [Cites] N Engl J Med. 1971 Apr 15;284(15):878-81 [5549830.001]
  • [Cites] Res Commun Chem Pathol Pharmacol. 1974 Sep;9(1):85-95 [4216060.001]
  • [Cites] J Steroid Biochem. 1975 May;6(5):673-6 [1186250.001]
  • [Cites] Cancer Res. 1977 Jan;37(1):67-75 [830422.001]
  • [Cites] Chem Biol Interact. 1986 Sep;59(2):173-84 [3769051.001]
  • [Cites] Mol Pharmacol. 1988 Jan;33(1):120-6 [3122017.001]
  • [Cites] Arch Environ Health. 1987 Nov-Dec;42(6):333-9 [3125795.001]
  • [Cites] Am J Epidemiol. 1989 Feb;129(2):395-406 [2492144.001]
  • [Cites] Cancer Res. 1990 Dec 1;50(23):7677-81 [2174729.001]
  • [Cites] J Natl Cancer Inst. 1994 Apr 20;86(8):589-99 [8145274.001]
  • [Cites] J Cardiovasc Surg (Torino). 1994 Dec;35(6):543-7 [7698972.001]
  • [Cites] Early Hum Dev. 1995 Apr 14;41(2):111-27 [7601016.001]
  • [Cites] Chemosphere. 1995 Aug;31(4):3017-23 [7552046.001]
  • [Cites] Arch Environ Contam Toxicol. 1995 Oct;29(3):334-43 [7487157.001]
  • [Cites] Environ Health Perspect. 1994 May;102(5):464-9 [8593850.001]
  • [Cites] Environ Health Perspect. 1995 Sep;103 Suppl 6:117-22 [8549457.001]
  • [Cites] Cancer Causes Control. 1995 Nov;6(6):551-66 [8580305.001]
  • [Cites] Environ Health Perspect. 1995 Oct;103 Suppl 7:141-5 [8593861.001]
  • [Cites] Biol Reprod. 1997 May;56(5):1147-57 [9160713.001]
  • [Cites] Environ Health Perspect. 1997 Apr;105 Suppl 3:577-81 [9167998.001]
  • [Cites] Toxicol Appl Pharmacol. 1997 Jul;145(1):111-23 [9221830.001]
  • [Cites] Environ Health Perspect. 1997 Oct;105(10):1030-2 [9349835.001]
  • [Cites] Toxicol Appl Pharmacol. 1997 Nov;147(1):93-100 [9356311.001]
  • [Cites] Ecotoxicol Environ Saf. 1997 Dec;38(3):281-5 [9469881.001]
  • [Cites] Toxicol Sci. 1998 Jan;41(1):62-76 [9520342.001]
  • [Cites] Chemosphere. 1997 Feb;34(4):835-48 [9569946.001]
  • [Cites] Am J Ind Med. 1998 Jul;34(1):6-14 [9617382.001]
  • [Cites] J Pediatr. 1999 Jan;134(1):33-41 [9880446.001]
  • (PMID = 16079073.001).
  • [ISSN] 0091-6765
  • [Journal-full-title] Environmental health perspectives
  • [ISO-abbreviation] Environ. Health Perspect.
  • [Language] ENG
  • [Grant] United States / PHS HHS / / 16652
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Environmental Pollutants; DFC2HB4I0K / Polychlorinated Biphenyls
  • [Other-IDs] NLM/ PMC1280343
  •  go-up   go-down


84. Ma QL, Liu DR, Guo YQ, Shi B, Song ZY, Tian YC: [Prognostic analysis of N2 non-small cell lung cancer]. Zhonghua Wai Ke Za Zhi; 2009 Jul 15;47(14):1058-60
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prognostic analysis of N2 non-small cell lung cancer].
  • OBJECTIVE: To evaluate the surgical therapeutic strategy and prognostic factors for non-small cell lung cancer (NSCLC) with mediastinal lymph node metastasis (N2).
  • The procedure of operation (lobectomy, pneumonectomy and palliative resection), histological classification (squamous cell carcinoma, adenocarcinoma, mixed carcinoma, and large cell carcinoma and others), T primary tumor status, and adjuvant therapy were analyzed to determine their impact on the 5-year survival rate.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / surgery. Lung Neoplasms / surgery

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19781268.001).
  • [ISSN] 0529-5815
  • [Journal-full-title] Zhonghua wai ke za zhi [Chinese journal of surgery]
  • [ISO-abbreviation] Zhonghua Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


85. Suzuki T, Suzuki T, Shinoda M, Takashi H, Yamaguchi H, Murayama M, Kamiya T, Morise K, Tashiro K, Kimura M, Yamagishi S, Ando T, Goto H: [An autopsy case of colon cancer associated ulcerative colitis complicated focal squamous cell carcinoma]. Nihon Shokakibyo Gakkai Zasshi; 2007 May;104(5):684-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [An autopsy case of colon cancer associated ulcerative colitis complicated focal squamous cell carcinoma].
  • At autopsy, the histological examination showed many mucinous adenocarcinoma and signet ring cell carcinoma with dysplasia.
  • There were also some areas of squamous cell carcinoma with squamous metaplasia and dysplasia far from rectum.
  • Squamous cell carcinoma and adenosquamous cell carcinoma of the colon are rare complications of ulcerative colitis.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Colitis, Ulcerative / complications. Colonic Neoplasms / pathology
  • [MeSH-minor] Adult. Carcinoma, Adenosquamous / pathology. Carcinoma, Signet Ring Cell / pathology. Female. Humans. Neoplasms, Multiple Primary / pathology

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • Genetic Alliance. consumer health - Ulcerative Colitis.
  • MedlinePlus Health Information. consumer health - Ulcerative Colitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17485949.001).
  • [ISSN] 0446-6586
  • [Journal-full-title] Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology
  • [ISO-abbreviation] Nihon Shokakibyo Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


86. Gatlez J, Hendlisz A, Legendre H, Sirtaine N, Debroux S, Awada A: [Colorectal epidermoid carcinoma and paraneoplastic hypercalcemia]. Acta Clin Belg; 2007 Nov-Dec;62(6):433-7
Genetic Alliance. consumer health - Epidermoid Carcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Colorectal epidermoid carcinoma and paraneoplastic hypercalcemia].
  • [Transliterated title] Carcinome épidermoïde colorectal et hypercalcémie paranéoplasique.
  • The squamous cell carcinoma and the adenosquamous cell carcinoma of the colon and rectum are not well know and rare tumours.
  • We report a case of squamous cell carcinoma of the recto-sigmoid who relapses in the liver after surgery of the primary tumour with paraneoplasic hypercalcaemia.
  • We will discuss the pathogenesis, prognosis, associated conditions, clinical features and treatment strategies of squamous and adenosquamous cell carcinoma of the colon and the rectum.
  • [MeSH-major] Carcinoma, Adenosquamous / secondary. Hypercalcemia / etiology. Paraneoplastic Syndromes / etiology. Sigmoid Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18351188.001).
  • [ISSN] 1784-3286
  • [Journal-full-title] Acta clinica Belgica
  • [ISO-abbreviation] Acta Clin Belg
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Belgium
  •  go-up   go-down


87. Yokota H, Matoba M, Tonami H, Hasegawa T, Saito H, Kurose N: Imaging findings in primary adenosquamous carcinoma of the liver: a case report. Clin Imaging; 2007 Jul-Aug;31(4):279-82
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imaging findings in primary adenosquamous carcinoma of the liver: a case report.
  • Adenosquamous cell carcinoma is characterized by both squamous and glandular components, and is a rare disease of the liver that is the subject of few reports in the literature.
  • We present a case in which the imaging findings on CT, MRI, and hepatic arteriography, as well as pathological correlation of the tumor and the clinical history, aided in including this entity in the differential diagnosis.
  • [MeSH-major] Carcinoma, Adenosquamous / radiography. Liver Neoplasms / radiography. Magnetic Resonance Imaging. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17599625.001).
  • [ISSN] 0899-7071
  • [Journal-full-title] Clinical imaging
  • [ISO-abbreviation] Clin Imaging
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


88. Song HG, Yoo KS, Ju NR, Park JC, Jung JO, Shin WG, Moon JH, Kim JP, Kim KO, Park CH, Hahn T, Park SH, Kim JH, Lee IJ, Min SK, Park CK: [A case of adenosquamous carcinoma of the papilla of Vater]. Korean J Gastroenterol; 2006 Aug;48(2):132-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of adenosquamous carcinoma of the papilla of Vater].
  • Adenosquamous carcinoma of the papilla of Vater is a rare tumor and only a few cases have been reported so far.
  • Here, we report a case of adenosquamous carcinoma in a 76-year-old male who presented with jaundice and right upper quadrant abdominal pain.
  • Histopathological inspection of the biopsied specimens from mass showed adenosquamous cell carcinoma of the papilla of Vater.
  • This is the first case report on adenosquamous carcinoma of the papilla of Vater in Korea.
  • [MeSH-major] Ampulla of Vater / pathology. Carcinoma, Adenosquamous / diagnosis
  • [MeSH-minor] Aged. Cell Differentiation. Humans. Immunohistochemistry. Male. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16929159.001).
  • [ISSN] 1598-9992
  • [Journal-full-title] The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
  • [ISO-abbreviation] Korean J Gastroenterol
  • [Language] kor
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Korea (South)
  •  go-up   go-down


89. Fujiu K, Sakuma H, Shio Y, Suzuki H, Mori M: [A case of non-Hodgkin's lymphoma after chemotherapy for cancer of unknown origin]. Gan To Kagaku Ryoho; 2008 Nov;35(11):1907-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Computed tomography(CT)scans showed a swelling of the superior mediastinal lymph node and a tumor of the right lobe of thyroid gland.
  • Pathological findings of the lymph node showed adenosquamous cell carcinoma, but no malignant lesion was found in the thyroid gland.
  • Post-operative systemic survey failed to identify the origin of the adenosquamous cell carcinoma.
  • Seven months later, CT and positron emission tomography revealed swelling of the mediastinal lymph nodes and a tumor in the left abdominal tumor.
  • An open biopsy of the abdominal tumor demonstrated non-Hodgkin's lymphoma, mature B cell type, follicular lymphoma, grade 1.
  • Radiotherapy was done for the malignant lymphoma, and radiochemotherapy for the mediastinal lymph nodes.
  • Seven months later, the patient died of systemic metastases of the adenosquamous cell carcinoma.
  • [MeSH-minor] Aged. Biomarkers, Tumor / blood. Biopsy. Carcinoma, Adenosquamous / drug therapy. Carcinoma, Adenosquamous / pathology. Carcinoma, Adenosquamous / radiography. Carcinoma, Adenosquamous / surgery. Combined Modality Therapy. Humans. Male. Tomography, X-Ray Computed. Treatment Failure

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19011340.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


90. Vasiljevic M, Pazin V, Dzatic O, Jeremic D: Primary fallopian tube carcinoma in a 51-year-old postmenopausal woman--case report. Eur J Gynaecol Oncol; 2007;28(6):531-3

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary fallopian tube carcinoma in a 51-year-old postmenopausal woman--case report.
  • The case of a 51-year-old woman with a primary carcinoma of the left fallopian tube is presented.
  • Histopathological examination revealed primary adenosquamous cell carcinoma of the fallopian tube.
  • [MeSH-major] Fallopian Tube Neoplasms / diagnosis. Postmenopause

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18179157.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


91. Iwanami T, Uramoto H, Baba T, Takenaka M, Yokoyama E, Oka S, So T, Ono K, So T, Takenoyama M, Hanagiri T, Iwata T, Inoue M, Yasumoto K: [Treatment recommendations for adrenal metastasis of non-small cell lung cancer]. Kyobu Geka; 2010 Dec;63(13):1101-6; discussion 1106-8
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment recommendations for adrenal metastasis of non-small cell lung cancer].
  • To evaluate the optimum treatment strategy for metastatic adrenal tumors derived from non-small cell lung cancer (NSCLC), we retrospectively analyzed 17 consecutive cases (8 resection cases: 4 synchronous and 4 metachronous: 9 non-resection cases: 3 synchronous and 6 metachronous) who received surgical resection for NSCLC.
  • Of these, 9, 3, 2, 2, and 1 patient (s) were diagnosed as having adenocarcinoma, squamous cell carcinoma, pleomorphic carcinoma, large cell carcinoma, and adenosquamous cell carcinoma, respectively.
  • The mean time to progression from treatment of metachronous adrenal metastasis to disease progression was 8.9 months.
  • [MeSH-major] Adrenal Gland Neoplasms / secondary. Adrenal Gland Neoplasms / therapy. Carcinoma, Non-Small-Cell Lung / pathology. Lung Neoplasms / pathology


92. Stelow EB, Mills SE: Squamous cell carcinoma variants of the upper aerodigestive tract. Am J Clin Pathol; 2005 Dec;124 Suppl:S96-109
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Squamous cell carcinoma variants of the upper aerodigestive tract.
  • Squamous cell carcinoma (SCC) is by far the most common malignancy of the upper aerodigestive tract.
  • Certain variants, however, can histologically mimic benign and other malignant diseases.
  • In such cases, correct diagnosis is important for prognostic and therapeutic reasons.
  • This article discusses the clinicopathologic features of the upper aerodigestive tract variants of SCC, including verrucous carcinoma, papillary squamous cell carcinoma, basaloid squamous cell carcinoma, spindle cell carcinoma, adenosquamous carcinoma, adenoid squamous cell carcinoma, and undifferentiated carcinoma.
  • It also discusses the differential diagnoses that must be considered and the use of ancillary testing, especially immunohistochemical analysis, for determining the correct diagnosis.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Digestive System Neoplasms / pathology
  • [MeSH-minor] Carcinoma, Adenosquamous / pathology. Carcinoma, Basal Cell / pathology. Carcinoma, Papillary / pathology. Humans

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16468420.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 109
  •  go-up   go-down


93. Otrock ZK, Mahfouz RA, Salem ZM: Four primary tumors of lung, bladder, prostate, and breast in a male patient. South Med J; 2005 Sep;98(9):946-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It is a case of both synchronous and metachronous primary malignant neoplasms occurring in four different organs.
  • Immunohistochemical stains showed tumor cell nuclei to be negative for p53 over-expression.
  • The tumors included an adenosquamous cell carcinoma of the lung, transitional cell carcinoma of the urinary bladder, and adenocarcinomas of the prostate and the breast.
  • We also review the medical literature for the possible causes of multiple primary malignant neoplasms.
  • [MeSH-major] Breast Neoplasms / complications. Carcinoma / complications. Lung Neoplasms / complications. Prostatic Neoplasms / complications. Urologic Neoplasms / complications
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cystectomy. Fatal Outcome. Humans. Lymph Node Excision. Lymphatic Metastasis. Male. Mastectomy. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / drug therapy. Radiotherapy, Adjuvant. Shock, Septic / complications. Spinal Neoplasms / complications. Spinal Neoplasms / diagnosis. Spinal Neoplasms / secondary. Urinary Diversion

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16217994.001).
  • [ISSN] 0038-4348
  • [Journal-full-title] Southern medical journal
  • [ISO-abbreviation] South. Med. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


94. Kobayashi N, Higurashi T, Iida H, Mawatari H, Endo H, Nozaki Y, Tomimoto A, Yoneda K, Akiyama T, Fujita K, Takahashi H, Yoneda M, Inamori M, Abe Y, Kirikoshi H, Kubota K, Saito S, Ueno N, Nakajima A, Yamanaka S, Inayama Y: Adenosquamous carcinoma of the pancreas associated with humoral hypercalcemia of malignancy (HHM). J Hepatobiliary Pancreat Surg; 2008;15(5):531-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenosquamous carcinoma of the pancreas associated with humoral hypercalcemia of malignancy (HHM).
  • We report a rare case of adenosquamous carcinoma of the pancreas associated with humoral hypercalcemia of malignancy (HHM) in which parathyroid hormone-related protein (PTH-rP) was identified as the causative factor of hypercalcemia.
  • Autopsy demonstrated that the neoplasm in the pancreas showed an abrupt histological transition from adenocarcinoma to squamous cell carcinoma.
  • PTH-rP was identified in the primary pancreatic tumor cells by immunohistochemical examination and a reverse-transcription polymerase chain reaction (RTPCR) method.
  • This is a very rare report of adenosquamous cell carcinoma of the pancreas associated with HHM.
  • [MeSH-major] Carcinoma, Adenosquamous / complications. Hypercalcemia / etiology. Pancreatic Neoplasms / complications

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18836809.001).
  • [ISSN] 0944-1166
  • [Journal-full-title] Journal of hepato-biliary-pancreatic surgery
  • [ISO-abbreviation] J Hepatobiliary Pancreat Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Parathyroid Hormone-Related Protein
  •  go-up   go-down


95. Morinaga R, Matsunaga N, Iwata A, Kishi K, Tokimatsu I, Nagai H, Kadota J: [A case of diaphragmatic paralysis caused by herpes zoster after anticancer chemotherapy]. Nihon Kokyuki Gakkai Zasshi; 2007 Feb;45(2):166-9
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 61-year-old woman who had been followed up after resection of lung cancer (adenosquamous cell carcinoma), was admitted to our hospital because of recurrence.
  • [MeSH-minor] Carcinoma, Adenosquamous / drug therapy. Carcinoma, Adenosquamous / surgery. Cisplatin / administration & dosage. Drug Administration Schedule. Female. Humans. Lung Neoplasms / drug therapy. Lung Neoplasms / surgery. Lymph Node Excision. Middle Aged. Pneumonectomy. Vinblastine / administration & dosage. Vinblastine / analogs & derivatives

  • Genetic Alliance. consumer health - paralysis.
  • MedlinePlus Health Information. consumer health - Shingles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. VINORELBINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17352174.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 5V9KLZ54CY / Vinblastine; Q20Q21Q62J / Cisplatin; Q6C979R91Y / vinorelbine
  •  go-up   go-down


96. Sugimoto Y, Semba H, Fujii S, Furukawa E, Kurano R: [Clinical analysis of primary lung cancer with a thin-walled cavity to explain the mechanism of thin-walled cavity formation]. Nihon Kokyuki Gakkai Zasshi; 2007 Jun;45(6):460-4
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Histologically, there were 5 cases of adenocarcinoma, 2 of squamous cell carcinoma, and 1 of adenosquamous cell carcinoma.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / radiography. Carcinoma, Adenosquamous / pathology. Carcinoma, Adenosquamous / radiography. Carcinoma, Squamous Cell / radiography. Lung Neoplasms / pathology. Lung Neoplasms / radiography

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17644941.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 13
  •  go-up   go-down


97. Teramoto N, Nishimura R, Saeki T, Nogawa T, Hiura M: Adenoid basal carcinoma of the uterine cervix: report of two cases with reference to adenosquamous carcinoma. Pathol Int; 2005 Jul;55(7):445-52
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenoid basal carcinoma of the uterine cervix: report of two cases with reference to adenosquamous carcinoma.
  • Adenoid basal carcinoma (ABC) of the uterine cervix is a rare neoplasm with excellent prognosis.
  • Differential diagnosis between ABC and an ABC-like lesion of adenosquamous cell carcinoma (ASC) of the cervix is important due to their contrasting prognosis.
  • The two ABC were incidentally found in the uterine cervix of 69-year-old and 59-year-old Japanese women due to cervical intraepithelial neoplasia grade 3 and to squamous cell carcinoma, respectively.
  • An ABC-like lesion was defined as basaloid cell nests simulating ABC, but with some features indicating malignant potential.
  • However, the differential diagnosis was sometimes difficult because two of seven ABC-like lesions were originally diagnosed as ABC.
  • [MeSH-major] Carcinoma, Adenoid Cystic / pathology. Carcinoma, Adenosquamous / pathology. Carcinoma, Basal Cell / pathology. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Keratin-7. Keratin-8. Keratins / analysis. Ki-67 Antigen / analysis. Middle Aged

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15982222.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / KRT7 protein, human; 0 / KRT8 protein, human; 0 / Keratin-7; 0 / Keratin-8; 0 / Ki-67 Antigen; 68238-35-7 / Keratins
  •  go-up   go-down


98. Zhao ZL, Huang QY, Xu S, Zhang L, Zhao HR: [Expression of promyelocytic leukaemia protein in lung carcinomas and clinical significance thereof]. Zhonghua Yi Xue Za Zhi; 2006 Dec 19;86(47):3362-6
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of promyelocytic leukaemia protein in lung carcinomas and clinical significance thereof].
  • OBJECTIVE: To investigate the expression of promyelocytic leukaemia (PML) protein in lung carcinomas and the clinical significance thereof.
  • METHODS: A tumor tissue microarray with lung samples from 148 patients with lung carcinoma and 5 patients with pulmonary benign tumor, and 7 patients with other benign diseases resected during operation.
  • RESULTS: Four cases of lung carcinoma were excluded because their available cores were less than 3.
  • The remaining 144 lung carcinoma cases included 45 cases with squamous cell carcinoma, 62 with adenocarcinoma, 23 with small cell lung carcinoma (SCLC), 7 with large cell carcinoma, 5 with pleomorphic carcinoma, 1 with carcinoid, and 1 with adenosquamous carcinoma.
  • The rates of PML expression on cell nuclei were 31.4% and 8.7% respectively in the non-small cell lung carcinoma (NSCLC) and SCLC samples (chi(2) = 4.968, P = 0.026).
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / metabolism. Carcinoma, Small Cell / metabolism. Lung Neoplasms / metabolism. Neoplasm Proteins / biosynthesis. Nuclear Proteins / biosynthesis. Transcription Factors / biosynthesis. Tumor Suppressor Proteins / biosynthesis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17313836.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / Nuclear Proteins; 0 / Transcription Factors; 0 / Tumor Suppressor Proteins; 143220-95-5 / PML protein, human
  •  go-up   go-down


99. Gu MJ, Choi JH, Park WK, Chang JC, Kim HJ: [Primary adenosquamous carcinoma of the liver: a case report]. Korean J Hepatol; 2005 Mar;11(1):86-9
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary adenosquamous carcinoma of the liver: a case report].
  • Primary adenosquamous cell carcinoma of the liver, a variant of cholangiocarcinoma is very rare disease and its prognosis is known to be very poor.
  • We describe here a case of primary adenosquamous carcinoma of the liver.
  • Needle biopsy of the mass was done and the histologic diagnosis was cholangiocarcinoma.
  • Microscopically, the tumor was composed of both adenocarcinoma and squamous cell carcinoma.
  • [MeSH-major] Carcinoma, Adenosquamous / diagnosis. Liver Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15788889.001).
  • [ISSN] 1738-222X
  • [Journal-full-title] The Korean journal of hepatology
  • [ISO-abbreviation] Korean J Hepatol
  • [Language] kor
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Korea (South)
  •  go-up   go-down


100. Kuroda N, Oonishi K, Inoue K, Ohara M, Mizuno K, Lee GH: Lymphoepithelioma-like carcinoma of the stomach associated with adenosquamous carcinoma. Med Mol Morphol; 2010 Sep;43(3):170-3
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphoepithelioma-like carcinoma of the stomach associated with adenosquamous carcinoma.
  • Lymphoepithelioma-like carcinoma and adenosquamous carcinoma of the stomach are relatively rare tumors.
  • To date, there are no reports on lymphoepithelioma-like carcinoma of the stomach associated with adenosquamous carcinoma.
  • Histological examination of the gastric tumor showed the coexistence of lymphoepithelioma-like carcinoma and adenosquamous carcinoma.
  • Neoplastic cells of the latter were immunoreactive for p63 and keratin 903, and Alcian blue stain detected acid mucin in glandular lumens.
  • This pattern resembled mucoepidermoid carcinoma in the salivary gland.
  • Finally, this is the first case of gastric lymphoepithelioma-like carcinoma associated with adenosquamous carcinoma, and clinicians and pathologists should recognize the presence of such a tumor.
  • [MeSH-major] Carcinoma, Adenosquamous / pathology. Lymphoma / pathology. Stomach Neoplasms / pathology

  • Genetic Alliance. consumer health - Stomach carcinoma.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20857266.001).
  • [ISSN] 1860-1499
  • [Journal-full-title] Medical molecular morphology
  • [ISO-abbreviation] Med Mol Morphol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA-Binding Proteins; 0 / Ribosomal Proteins; 135844-68-7 / RPL22 protein, human
  •  go-up   go-down






Advertisement